Autosomal Dominant Nonsyndromic Hearing Loss 7

Mendelian MONDO:0011074 Pathograph 10 Show in embeddings browser Autosomal Dominant Nonsyndromic Hearing Loss

DFNA7 is the dominant, hearing-only phenotype produced by heterozygous variants in LMX1A, a LIM-homeodomain transcription factor. The gene is best known from mouse developmental genetics, where it acts as a selector gene that partitions the otic vesicle into neural, sensory and non-sensory territory and is required to build the endolymphatic duct, the semicircular canals and the stria vascularis. The point that organises this entry is that the human dominant disease is not a milder version of that developmental catastrophe. Homozygous null mice have grossly malformed inner ears and no endocochlear potential; heterozygous mice hear normally. Human heterozygotes, by contrast, are born with anatomically normal cochleae on imaging and then lose hearing over years or decades. The Dutch families in which DFNA7 was established were explicit about the inference this forces: one wild-type copy of LMX1A appears to be enough to build the ear but not enough to keep it working. Whatever DFNA7 is, it is a maintenance failure sitting downstream of a developmental transcription factor, and the mouse null is a model of the gene's job rather than a model of the disease. The molecular mechanism is haploinsufficiency, and this has been tested rather than assumed. Reporter assays across the reported allelic series show reduced transactivation for missense, nonsense and frameshift alleles alike; plasmid titration and transcript stability chase experiments specifically excluded a dominant-negative effect. Severity tracks the size of the transcriptional deficit, with the most transcriptionally damaging allele reported so far found in the one subject with congenital severe-to-profound deafness. Two clinical features recur often enough to be worth knowing at the bedside. Hearing loss in DFNA7 is characteristically asymmetric between the two ears, unusually so for a dominant nonsyndromic form, and roughly half of affected individuals have measurable vestibular dysfunction whether or not they complain of it. Intrafamilial variability is wide: within single families, onset ranges from infancy to mid-adulthood and severity from mild to profound on the same allele, so a mildly affected parent gives little prognostic information about an affected child. LMX1A is not exclusively dominant. A homozygous C-terminal missense variant has been reported in a consanguineous Pakistani family with severe-to-profound recessive hearing impairment, so the gene spans both inheritance modes. MONDO carries no separate term for that recessive phenotype, so it is curated here as a second inheritance block and a second genetic entry rather than being left uncovered. One caveat about the identity of this entry. DFNA7 is a locus, defined in 1996 by linkage in a large Norwegian family to a 22 cM interval on 1q21-q23, and MONDO's definition still reflects that: it names the material basis as variation in the chromosome region rather than as a gene. LMX1A sits at 1q23.3, inside that interval, but it was tied to dominant hearing loss 22 years later in unrelated Dutch families, and no report identifies an LMX1A variant in the founding Norwegian pedigree. The gene-to-locus assignment therefore rests on positional plausibility plus independent families, not on solving the original family.

Ask OpenScientist

Ask a research question about Autosomal Dominant Nonsyndromic Hearing Loss 7. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
4
Pathophys.
6
Phenotypes
3
Gaps
10
Pathograph
2
Genes
3
Medical Actions
2
Models
1
Deep Research
👪

Inheritance

2
Autosomal dominant HP:0000006
Heterozygous LMX1A variants segregating with hearing loss in multi-generation pedigrees, with de novo occurrence documented for at least two alleles. Penetrance appears high but expressivity is markedly variable within families.
Autosomal dominant inheritance
Show evidence (3 references)
PMID:29754270 SUPPORT Human Clinical
"Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
The founding dominant families and the heterozygous state of the alleles.
PMID:29754270 SUPPORT Human Clinical
"One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding."
A de novo dominant allele, which matters for counselling because an apparently isolated case does not exclude LMX1A.
PMID:36519758 SUPPORT Human Clinical
"This C-terminal frameshift mutation co-segregated with autosomal dominant (AD) NSHL in a four-generation Chinese family"
Four-generation cosegregation of a truncating allele with dominant disease.
Autosomal recessive HP:0000007
A second, much rarer inheritance mode for the same gene. A homozygous C-terminal missense variant, p.Ile369Thr, was reported in a consanguineous Pakistani family with severe-to-profound hearing impairment. It is curated inside this entry rather than separately because MONDO has no distinct term for an LMX1A-related recessive nonsyndromic hearing loss, and because the two modes are mechanistically continuous: the recessive C-terminal residue interacts with homeodomain residue Val241, which is itself mutated in dominant families.
Autosomal recessive inheritance
Show evidence (3 references)
PMID:29971487 SUPPORT Human Clinical
"In this study, we used a homozygosity mapping and exome sequencing strategy to study a consanguineous Pakistani family with autosomal recessive severe-to-profound hearing impairment."
The recessive pedigree and the mapping strategy that identified it.
PMID:29971487 SUPPORT Human Clinical
"Our results suggest that LMX1A is involved in both human autosomal recessive and dominant sensorineural hearing impairment."
The authors' conclusion that the gene spans both inheritance modes.
PMID:42253511 SUPPORT Human Clinical
"Pathogenic variants in the LIM-homeodomain transcription factor LMX1A represent a rare yet critical etiology for autosomal dominant nonsyndromic hearing loss 7 (DFNA7) and less frequently, its autosomal recessive counterpart (ARNSHL)."
Independent confirmation that the recessive counterpart exists and is the less common of the two, which is why it is a block within this entry rather than an entry of its own.
?

Discussions and Knowledge Gaps

3
Every Lmx1a animal model of hearing loss is a homozygous null with a malformed inner ear, while DFNA7 is a heterozygous, anatomically normal ear that deteriorates. Does mouse Lmx1a heterozygosity really produce no auditory phenotype, or has it never been looked for with sufficiently sensitive or sufficiently aged measurements?
HUMAN MODEL MISMATCH lmx1a_dominant_model_gap
Attached to
pathophysiology#Impaired Maintenance of Cochleovestibular Function animal_models#Mouse
This is the central translational problem for DFNA7 and it is a mismatch rather than an absence of evidence. Three independent Lmx1a alleles have been characterised in mice and all report that heterozygotes hear normally, so the negative result is reproducible. But the reported ABR comparisons are made in young animals in studies designed around the homozygous phenotype, whereas the human disease is late-onset and progressive and in some individuals does not declare itself until mid-adulthood. A mouse tested at a few weeks old is not the right test of a phenotype whose human equivalent takes decades. The consequence is that the mechanistic claim this entry rests on, that one LMX1A copy builds an ear but cannot maintain it, has never been tested in an animal. So the competing developmental explanation offered in the original human description, that imaging-invisible developmental abnormalities set up later decline, remains equally live. Aged heterozygous Lmx1a mice with serial ABR and DPOAE, and cochlear histology at the end of that series, would separate the two, and a knock-in of a human homeodomain allele would be a stronger test than heterozygous null because human alleles include missense substitutions with residual activity rather than clean deletions.
Proposed experiments
Aged heterozygous Lmx1a mouse auditory phenotyping
exp_dfna7_aged_heterozygous_lmx1a_abr
Serial ABR and DPOAE in heterozygous Lmx1a mice through to old age, with cochlear and vestibular histology at endpoint, compared against wild-type littermates. Powered for a progressive threshold shift rather than for a categorical deaf or hearing call.
Would support
pathophysiology#Impaired Maintenance of Cochleovestibular Function
Would refute
pathophysiology#Impaired Maintenance of Cochleovestibular Function
Supporting outcome
  • Heterozygotes show normal thresholds in early adulthood and a progressive age-dependent threshold elevation with hair cell or strial degeneration on endpoint histology.
Refuting outcome
  • Heterozygotes remain audiometrically and histologically indistinguishable from wild-type littermates into old age, which would place the human mechanism outside simple mouse gene dosage and favour either the subtle-developmental explanation or a human-specific requirement.
Show evidence (4 references)
PMID:23226461 SUPPORT Model Organism
"The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
The mismatch itself: the genotype that causes human DFNA7 causes no measured auditory phenotype in the mouse.
PMID:29754270 SUPPORT Human Clinical
"Although Lmx1a mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic features were present in the participating subjects of either family."
The mismatch extends beyond the ear. Mouse Lmx1a mutants are syndromic across several organ systems; human LMX1A heterozygotes are not, so mouse extra-auditory phenotypes should not be used to predict human ones.
PMID:29754270 SUPPORT Human Clinical
"Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families."
The competing developmental explanation that the missing animal experiment would test, stated by the authors as an explicit alternative to the maintenance reading.
+ 1 more reference
Why is DFNA7 hearing loss asymmetric? What makes a cell-autonomous transcription factor dosage deficit, present equally in both ears, produce different thresholds on the two sides?
KNOWLEDGE GAP lmx1a_asymmetry_mechanism
Attached to
phenotypes#Asymmetric Sensorineural Hearing Loss pathophysiology#Impaired Maintenance of Cochleovestibular Function
Asymmetry is the most distinctive clinical feature of DFNA7 and nothing in the curated mechanism explains it. A germline heterozygous variant is present in both cochleae at the same dosage, so a purely dose-dependent maintenance failure predicts symmetric decline. Asymmetry implies that the deficit is permissive rather than deterministic, with something stochastic or environmental deciding how fast each ear declines, but what that something is has not been investigated. This is not idle. If a second, modifiable factor determines which ear declines first, it is a therapeutic target that the transcription factor itself is not; and if asymmetry is instead stochastic clonal drift in a maintenance process, that argues the window for intervention is set per ear rather than per patient. Nobody has reported longitudinal audiometry designed to distinguish these, nor tested whether the more-affected ear is predicted by noise history, otologic history or side dominance.
Show evidence (2 references)
PMID:35711095 SUPPORT Human Clinical
"It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied."
Establishes the phenomenon as near-universal in the series while explicitly noting that its degree varies, which is the variability the gap is about.
PMID:42253511 SUPPORT Human Clinical
"Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
Between-individual variability on one allele within one family, the same puzzle as between-ear asymmetry seen at a different scale, and equally unexplained by dosage.
Does the founding Norwegian DFNA7 family actually carry an LMX1A variant? The locus and the gene were established 22 years apart in different populations, and no report connects them in the original pedigree.
KNOWLEDGE GAP dfna7_locus_to_gene_assignment
Attached to
disease#Autosomal Dominant Nonsyndromic Hearing Loss 7 genetic#LMX1A
DFNA7 is a locus name, not a gene name. It was defined in 1996 by linkage in a large Norwegian family with progressive high-tone hearing loss to a 22 cM interval between D1S104 and D1S466 on 1q21-q23, and the paper noted that the region contained several attractive candidate genes. MONDO's definition of MONDO:0011074 still describes the material basis as variation in that chromosome region rather than as a gene. LMX1A lies at 1q23.3, inside the interval, and heterozygous LMX1A variants were shown to cause dominant progressive hearing impairment in 2018 in two unrelated Dutch families. Every subsequent family in the literature is an independent LMX1A family. But no published report identifies an LMX1A variant in the Norwegian pedigree, so the equation of the locus with the gene rests on positional plausibility plus replication in other families rather than on solving the founding one. Two things follow. First, the phenotype MONDO attributes to DFNA7 is the Norwegian family's progressive high-tone loss, whereas the phenotype the LMX1A literature describes is progressive asymmetric loss across frequencies with vestibular involvement in about half of cases. Those are not obviously the same description, and if they are not the same disease the label is doing two jobs. Second, the interval is large and gene-dense, so an alternative gene in 1q21-q23 accounting for the Norwegian family is not excluded by anything published. This is recorded rather than resolved because it does not change how the entry is curated: everything in the pathograph below comes from molecularly confirmed LMX1A families. It changes what the entry's name should be taken to guarantee.
Show evidence (4 references)
PMID:8842739 SUPPORT Human Clinical
"Analysis of recombinant individuals maps the deafness gene (DFNA7) to a 22 cM region between D1S104 and D1S466."
The locus definition. A 22 cM interval is what the DFNA7 label originally denoted, and the founding paper stops at localisation.
PMID:8842739 SUPPORT Human Clinical
"The region contains several attractive candidate genes."
The founding authors' own statement that the interval held multiple candidates, which is why positional plausibility alone does not settle the assignment.
PMID:8842739 SUPPORT Human Clinical
"The present report describes a large Norwegian family with autosomal dominant non-syndromic, progressive high tone hearing loss with linkage to 1q21-q23."
Graded PARTIAL because it describes a phenotype that is not quite the one the LMX1A families show. High-tone loss is not the asymmetric, all-frequency picture reported for molecularly confirmed LMX1A carriers.
+ 1 more reference
⚙

Pathophysiology

4
LMX1A Haploinsufficiency
A single functional LMX1A allele remains. The reported alleles are heterogeneous in kind, including homeodomain missense substitutions that weaken DNA binding, nonsense alleles that remove the homeodomain entirely, and C-terminal frameshifts that delete the helix mediating LIM2-domain interaction. What unites them is the direction of the effect on protein dosage rather than any shared structural lesion. That this is dosage insufficiency and not interference by the mutant protein has been tested directly. Plasmid titration and Actinomycin D transcript-chase experiments corroborated haploinsufficiency and excluded a dominant-negative effect, and an earlier study reached the same conclusion for a de novo homeodomain allele. The distinction matters therapeutically: a haploinsufficiency mechanism is in principle addressable by raising expression of the remaining allele, whereas a dominant-negative one is not.
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Animal models
Lmx1a dreher null mouse Mouse fails to recapitulate Included because it is the model most often cited when LMX1A is discussed, and because being explicit about what it does not show is more useful than omitting it. The dreher null defines the gene's developmental job comprehensively. It does not model a heterozygous dosage reduction.
Downstream
Reduced Transactivation of LMX1A Target Genes
Show evidence (3 references)
PMID:42253511 SUPPORT In Vitro
"Furthermore, plasmid titration experiments and Actinomycin D chase assays functionally corroborated the haploinsufficiency mechanism and excluded the dominant-negative effect."
The direct experimental test that separates haploinsufficiency from a dominant-negative mechanism.
PMID:32840933 SUPPORT In Vitro
"Further, our dominant LMX1A variant exerted pathogenic effects via haploinsufficiency rather than dominant-negative effect."
Independent replication of the haploinsufficiency conclusion on a different allele.
PMID:35254497 SUPPORT In Vitro
"We also provide further evidence for haploinsufficiency as the pathogenic mechanism underlying LMX1A-related ADHL."
A third independent group reaching the same mechanistic conclusion.
Reduced Transactivation of LMX1A Target Genes
LMX1A is a DNA-binding transcription factor, and every disease allele assayed so far reduces its ability to drive transcription of downstream targets in reporter systems. The structural routes differ. Homeodomain missense substitutions attenuate the protein-DNA interaction; a premature stop destroys the protein including the homeodomain; a C-terminal frameshift removes a helix required for LIM2-domain interaction and for protein-DNA binding, without triggering nonsense-mediated decay. The quantitative version of this node is what gives DFNA7 its genotype-phenotype correlation: the allele with the largest measured loss of transcriptional activity is the one found in congenital severe-to-profound deafness, while alleles with only moderately reduced activity are associated with later-onset progressive loss.
DNA-binding transcription factor activity GO:0003700 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased DNA-binding transcription factor activity (GO:0003700). GO:0003700 is a molecular function from the Gene Ontology. ↓ DECREASED
Animal models
Lmx1a mutanlallemand and Belly Spot and Deafness mice Mouse partially recapitulates These alleles establish in vivo what the human reporter assays measure in vitro: truncating Lmx1a lesions reduce transcript levels and reduce expression of downstream targets. That is the node being modelled, and it is modelled well.
Downstream
Impaired Maintenance of Cochleovestibular Function
Cochlear Hair Cell Apoptosis
Show evidence (4 references)
PMID:35711095 SUPPORT In Vitro
"Compared with the wild-type protein, all mutant LMX1A proteins had significantly reduced transactivation efficiency, indicating that the ability to elicit transcription of the downstream target genes of LMX1A was severely compromised."
Reduced transactivation across four structurally different novel alleles.
PMID:32840933 SUPPORT In Vitro
"Resultantly, p.Arg199Gly manifesting the most severe NSHL showed the biggest reduction of transcriptional activity in contrast with moderately reduced activity of p.Cys97Ser and p.Val241Leu associated with less severe progressive NSHL, proposing a genotype-phenotype correlation."
The dose-response between measured transcriptional deficit and clinical severity, which is what makes this node quantitative rather than merely present or absent.
PMID:35254497 SUPPORT In Vitro
"and one family with a novel variant in LMX1A (c.686C>A; p.(Ala229Asp)) that impairs its transcriptional activity"
A further allele independently shown to impair transcriptional activity.
+ 1 more reference
Impaired Maintenance of Cochleovestibular Function
The proposed human mechanism: reduced LMX1A dosage is compatible with building an anatomically normal inner ear but not with sustaining its function. The clinical observations behind this are that onset is typically late, the course is progressive, and computed tomography shows no cochleovestibular malformation in affected individuals. Two readings of this were offered in the original description and neither has been resolved. Either LMX1A has an ongoing postdevelopmental requirement in the cochleovestibular epithelium, or subtle developmental abnormalities below the resolution of clinical imaging set up a structure that degrades over time. The distinction is not academic: only the first predicts that raising LMX1A expression in an adult ear could help.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology. cochlear outer hair cell CL:0000601 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear outer hair cell (CL:0000601). CL:0000601 is a cell type from the Cell Ontology. vestibular hair cell CL:0000609 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vestibular hair cell (CL:0000609). CL:0000609 is a cell type from the Cell Ontology.
detection of mechanical stimulus involved in sensory perception of sound GO:0050910 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased detection of mechanical stimulus involved in sensory perception of sound (GO:0050910). GO:0050910 is a biological process from the Gene Ontology. ↓ DECREASED detection of mechanical stimulus involved in equilibrioception GO:0050973 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased detection of mechanical stimulus involved in equilibrioception (GO:0050973). GO:0050973 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Lmx1a mutanlallemand and Belly Spot and Deafness mice Mouse fails to recapitulate The mouse does not reproduce the human maintenance failure. Instead of an anatomically normal ear that deteriorates, homozygotes have an ear that was never built correctly, and heterozygotes have no phenotype at all.
Downstream
Progressive Sensorineural Hearing Impairment
Vestibular Dysfunction
Show evidence (3 references)
PMID:29754270 SUPPORT Human Clinical
"We propose that a single LMX1A wild-type copy is sufficient for normal development but insufficient for maintenance of cochleovestibular function."
The maintenance hypothesis stated by the group that established the disease.
PMID:29754270 SUPPORT Human Clinical
"The late-onset progressive phenotype and the absence of cochleovestibular malformations on computed tomography scans indicate that heterozygous defects of LMX1A do not result in severe developmental abnormalities in humans."
The imaging and natural-history observations that rule out a gross developmental lesion in human heterozygotes.
PMID:29754270 SUPPORT Human Clinical
"Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families."
Graded PARTIAL because it is the authors' own competing explanation for the same data. Curated deliberately so the node is not read as a settled postdevelopmental maintenance claim.
Cochlear Hair Cell Apoptosis
A candidate cellular endpoint, supported only in a cell line so far. In HEI-OC1 auditory cells, the C-terminal domain of LMX1A was shown to be important for mediating apoptosis, and cells carrying the heterozygous frameshift variant upregulated several hearing-loss-associated genes at the transcript level. This is included because it is the only cellular death mechanism yet proposed for DFNA7, and flagged as in vitro because no human or mouse cochlear histology exists for a heterozygous LMX1A allele.
cochlea auditory hair cell CL:4023120 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlea auditory hair cell (CL:4023120). CL:4023120 is a cell type from the Cell Ontology.
Downstream
Progressive Sensorineural Hearing Impairment
Show evidence (2 references)
PMID:36519758 SUPPORT In Vitro
"Furthermore, apoptosis assays suggested that the C-terminal domain of the LMX1A was important for mediating apoptosis in the cochlear hair cells."
Graded PARTIAL because the assay establishes a domain requirement in a cell line, not that hair cell apoptosis occurs in DFNA7 patients.
PMID:36519758 SUPPORT In Vitro
"We also found that the embryonic cells carrying with the heterozygous variant significantly expressed several upregulated HL-associated genes at transcriptional level."
A transcriptional consequence of the heterozygous allele in cells; supportive of a cell-autonomous effect but not of apoptosis in patient tissue.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Dominant Nonsyndromic Hearing Loss 7 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Ear 1
Asymmetric Sensorineural Hearing Loss FREQUENT Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Asymmetric sensorineural hearing impairment, annotated with Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
HPO has no term for asymmetric hearing impairment, so phenotype_term is bound to the accurate parent HP:0000407 and the asymmetry is carried by preferred_term. Binding a narrower but wrong term would be worse than this. Frequency is FREQUENT rather than VERY_FREQUENT, and the spread across sources is why. Asymmetry was universal among probands in the Korean five-family series but the founding Dutch families were mostly symmetric, two individuals in the Chinese family are described as symmetric, and the two-centre Korean series that counted with an explicit threshold found it in five of nine patients. The Korean cohort is the one that looked for asymmetry deliberately, which makes it the most sensitive series and also the most likely to be ascertainment dependent; grading to it alone would overstate the phenotype in the disease as a whole.
Show evidence (7 references)
PMID:35711095 SUPPORT Human Clinical
"It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied."
The primary observation, with its own caveat about varying extent.
PMID:35711095 SUPPORT Human Clinical
"For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss."
The diagnostic implication the authors draw.
PMID:42253511 SUPPORT Human Clinical
"cosegregating with progressive and asymmetric sensorineural hearing loss"
Independent replication of asymmetry in a Chinese family.
+ 4 more references
Other 5
Progressive Sensorineural Hearing Impairment VERY_FREQUENT HP:0000408 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive sensorineural hearing impairment (HP:0000408). HP:0000408 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29754270 SUPPORT Human Clinical
"Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
Progressive nonsyndromic hearing impairment in the founding families.
PMID:42253511 SUPPORT Human Clinical
"cosegregating with progressive and asymmetric sensorineural hearing loss"
Progression confirmed in an independent three-generation family.
Downsloping High-Frequency Audiogram Configuration FREQUENT High-frequency sensorineural hearing impairment HP:0001757 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is High-frequency sensorineural hearing impairment (HP:0001757). HP:0001757 is a phenotype from the Human Phenotype Ontology.
Bound to HP:0001757 for the high-frequency component, matching the DFNA41 and DFNB103 entries curated in the same batch. HPO has no term for a downsloping audiogram configuration as such, so the shape is carried by the phenotype name and description.
Show evidence (2 references)
PMID:29754270 SUPPORT Human Clinical
"Affected subjects had mild to profound HI with overall a downsloping audiogram configuration"
The audiogram configuration across the founding families, with its severity range.
PMID:42253511 SUPPORT Human Clinical
"Individual II: 2 exhibited high‐frequency SNHL with no documented history of exposure to known ototoxic agents."
High-frequency loss in an independent family, with ototoxic exposure explicitly excluded, which matters because the same audiogram shape is the signature of acquired causes.
Vestibular Dysfunction FREQUENT Abnormal vestibular function HP:0001751 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal vestibular function (HP:0001751). HP:0001751 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29754270 SUPPORT Human Clinical
"About half of the affected individuals displayed vestibular dysfunction and experienced symptoms thereof."
Frequency and symptomatic status of vestibular involvement in the founding families.
PMID:29754270 SUPPORT Human Clinical
"cVEMPs showed no responses up to 100 dBnHL in both subjects, indicating dysfunction of the saccule."
Localises the deficit to the saccule rather than leaving it at organ level, which is the kind of detail that distinguishes a measured vestibular phenotype from a reported symptom.
Congenital Severe-to-Profound Sensorineural Hearing Impairment OCCASIONAL Congenital sensorineural hearing impairment HP:0008527 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congenital sensorineural hearing impairment (HP:0008527). HP:0008527 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32840933 SUPPORT Human Clinical
"identification of a de novo, heterozygous, missense variant (c.595A > G; p.Arg199Gly) located in the homeodomain of LMX1A in a subject with congenital severe-to-profound deafness through Exome sequencing"
The congenital severe-to-profound case and the allele responsible.
PMID:36519758 SUPPORT Human Clinical
"In this family, the affected individuals exhibited the variable auditory phenotypes ranging from profound congenital deafness at birth or to mild/moderate HL in adulthood."
Congenital profound deafness at one end of a single family's range, which is also the clearest statement of how wide intrafamilial variability is.
Postlingual Sensorineural Hearing Impairment FREQUENT HP:0008596 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Postlingual sensorineural hearing impairment (HP:0008596). HP:0008596 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:42253511 SUPPORT Human Clinical
"Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
Documents onset extending to mid-adulthood, and the intrafamilial spread that makes prognosis from an affected relative unreliable.
PMID:41078281 SUPPORT Human Clinical
"Genetic testing revealed a variant of uncertain significance (p.Val241Ala) in LMX1A in a 56-year-old male with hearing loss since adolescence and his 12-year-old son, who failed newborn hearing screening."
A father-son pair spanning the range within one allele, adolescent onset in one and a failed newborn screen in the other.
🧬

Genetic Associations

2
LMX1A
Gene: LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (4 references)
PMID:42253511 SUPPORT Human Clinical
"Pathogenic variants in the LIM-homeodomain transcription factor LMX1A represent a rare yet critical etiology for autosomal dominant nonsyndromic hearing loss 7 (DFNA7) and less frequently, its autosomal recessive counterpart (ARNSHL)."
The gene-disease relationship, and the existence of a recessive counterpart.
PMID:41078281 SUPPORT Human Clinical
"Other pathogenic missense variants have previously been reported at the same Val241 site, suggesting that this location may be a hotspot for pathogenic variants contributing to NSHL, although further research is needed."
Graded PARTIAL because the authors explicitly hedge the hotspot claim; two substitutions at one residue is suggestive, not established.
PMID:35711095 SUPPORT Human Clinical
"In addition, Arg208*-induced premature termination of translation destroyed the structure of the LMX1A protein, including the DNA-binding homeodomain, and p.Gln297Thrfs*41 led to the loss of the C-terminal helix involved in LIM2 domain interaction."
The structural consequences of the truncating alleles, which is why alleles across the whole gene converge on reduced dosage.
+ 1 more reference
LMX1A homozygous C-terminal missense allele
Gene: LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:29971487 SUPPORT Human Clinical
"The p.Ile369Thr variant disrupts several C-terminal and homeodomain residue interactions, including an interaction with homeodomain residue p.Val241 that was previously found to be involved in autosomal dominant progressive HI."
The structural link between the recessive C-terminal allele and the dominant homeodomain residue, which is why the two inheritance modes are not unrelated accidents of the same gene.
💊

Medical Actions

3
Hearing Amplification
Hearing aids, fitted to the audiogram. There is no disease-modifying therapy for DFNA7. Asymmetric thresholds complicate fitting in a way they do not for symmetric dominant forms, and the wide intrafamilial variability means timing has to be individual rather than inherited from an affected parent's course.
Show evidence (2 references)
PMID:42253511 SUPPORT Human Clinical
"She was fitted with bilateral hearing aids, achieving near‐normal speech perception."
Amplification in a molecularly confirmed DFNA7 patient, with the outcome stated.
PMID:42253511 SUPPORT Human Clinical
"Individual II: 1 developed symmetric, bilateral severe SNHL across frequencies in early childhood and uses bilateral hearing aids."
A second aided individual in the same family, at the severe end of the range, which is what makes amplification the standing management rather than a single case.
Cochlear Implantation
Action: cochlear implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear implantation, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Cochlear implantation for an ear that has progressed to profound loss. The reported DFNA7 experience is one patient: her left ear deteriorated to profound loss while the asymmetry between the ears persisted, she underwent unilateral implantation, and her speech perception improved significantly at three and six months. Follow-up beyond six months is not reported for her. Asymmetry is what makes implantation a live question earlier in DFNA7 than in a symmetric dominant loss: one ear can reach implantable thresholds while the other is still aidable, so the decision is per-ear rather than per-patient.
Show evidence (3 references)
PMID:36140227 SUPPORT Human Clinical
"The patient eventually underwent unilateral CI, with significant improvement in her speech perception scores 3 and 6 months postoperatively (Figure 2c)."
The implantation and its short-term speech outcome in a DFNA7 patient.
PMID:36140227 SUPPORT Human Clinical
"In one patient (SB727), hearing deteriorated to profound hearing loss in her left ear and the asymmetric hearing loss remained."
The clinical situation that led to implantation, and the reason it was unilateral: one ear reached profound loss while the asymmetry persisted.
PMID:36140227 SUPPORT Human Clinical
"Our results provide evidence for favorable CI outcomes in patients with LMX1A-related DFNA7."
Graded PARTIAL because the authors' generalisation rests on a single implanted DFNA7 patient in this series. The direction is favourable; the sample is one.
Genetic Counselling with Audiologic Surveillance
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Counselling carries an unusual amount of weight here. Onset within a single family spans infancy to mid-adulthood on one allele, so an at-risk child cannot be reassured by a mildly affected parent, and a de novo allele has been documented, so an isolated case does not exclude the gene. Serial audiometry rather than a single normal test is what detects the progressive component.
Show evidence (2 references)
PMID:42253511 SUPPORT Human Clinical
"Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
The intrafamilial spread that makes prediction from a relative's course unsafe.
PMID:29754270 SUPPORT Human Clinical
"One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding."
Documented de novo occurrence, which is what makes a negative family history uninformative.
🔬

Diagnosis

1
Consider LMX1A when dominant hearing loss is asymmetric
DFNA7 is reached by gene-panel or exome sequencing rather than by any specific audiological test, but asymmetry is a usable prompt. Asymmetric thresholds in a dominant pedigree would ordinarily suggest an acquired or structural cause; in this disorder they are the rule. Imaging is typically normal, so a normal CT does not argue against the diagnosis, and in one severely affected proband high-resolution imaging showed bilateral cochlear aperture stenosis, so an abnormal scan does not argue against it either.
Show evidence (3 references)
PMID:35711095 SUPPORT Human Clinical
"For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss."
The authors' explicit diagnostic recommendation.
PMID:42253511 SUPPORT Human Clinical
"High-resolution imaging revealed bilateral cochlear aperture stenosis (CAS) in the severely affected proband."
Graded PARTIAL: a single severely affected proband with an imaging abnormality, in a disorder otherwise characterised by normal scans. Recorded so a curator does not treat normal imaging as an entry criterion.
PMID:29754270 SUPPORT Human Clinical
"recommend screening for HI in subjects with mono-allelic loss of LMX1A."
The reverse direction of ascertainment, and the practically useful one: someone found to have lost one LMX1A copy for another reason, such as a chromosomal deletion, should have their hearing checked.
📊

Prevalence

1
Worldwide, published cases
Cases In Literature Ultra Rare
Fewer than ten pathogenic LMX1A variants had been reported as of 2026.
Show evidence (1 reference)
PMID:41078281 SUPPORT Human Clinical
"Hereditary nonsyndromic hearing loss (NSHL) is a prevalent entity associated with over 150 known causative genes, including LMX1A, which has fewer than 10 reported pathogenic variants."
The size of the reported allelic series.
🐁

Animal Models

2
Lmx1a mutanlallemand and Belly Spot and Deafness mice
Two spontaneous Lmx1a alleles: mtl, a 3' splice-site point mutation in exon 4 producing a truncated protein affecting the homeodomain, and bsd, a genomic deletion removing exon 3 and truncating within the LIM2 domain. Both reduce Lmx1a transcript levels. Homozygotes are deaf by auditory brainstem response, circle and toss their heads, and lack endolymphatic ducts and semicircular canals with short cochlear ducts. Hmx2/3 and Pax2 expression are down-regulated, placing Lmx1a upstream of those factors in early inner ear morphogenesis.
Species
Mouse
Genotype
Lmx1a mtl and Lmx1a bsd, homozygous
Genes
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:23226461
Pathograph links
Reduced Transactivation of LMX1A Target Genes partially recapitulates fidelity: moderate These alleles establish in vivo what the human reporter assays measure in vitro: truncating Lmx1a lesions reduce transcript levels and reduce expression of downstream targets. That is the node being modelled, and it is modelled well.
Limitations: The relationship to DFNA7 stops there. Both alleles are recessive in the mouse. Heterozygous and wild-type littermates have normal hearing, so this system contains no animal in the genetic state that causes human DFNA7. The homozygous phenotype is a gross developmental malformation of the membranous labyrinth, which is precisely what human heterozygotes do not have on imaging. Reading these mice as a model of DFNA7 would invert the disease mechanism from maintenance failure to failed morphogenesis.
Readouts
Hmx2/Hmx3 and Pax2 expression in the developing otocyst
Direction: DECREASED
Interpretation: Downstream transcriptional targets fall when Lmx1a is truncated, the in vivo counterpart of the reduced transactivation measured for human alleles.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"Hmx2/3 and Pax2 expression are also down-regulated in mtl and bsd mutants, suggesting a role of Lmx1a upstream of these transcription factors in early inner ear morphogenesis."
The measured transcriptional consequence of Lmx1a truncation in vivo.
Auditory brainstem response by genotype
Direction: UNCHANGED
Interpretation: Deliberately recorded as unchanged, because the informative result here is the negative one: heterozygotes hear normally, so mouse Lmx1a dosage does not reproduce the human dominant phenotype.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
The genotype-phenotype split in the mouse, which is the basis for treating the model as informative about the gene rather than about the dominant disease.
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"Both mutations lead to a truncated LMX1A protein affecting the homeodomain (mtl) or LIM2-domain (bsd), which is critical for LMX1A protein function."
The molecular lesions, which are of the same structural classes as human DFNA7 alleles and so make the model informative for the transcriptional node.
Impaired Maintenance of Cochleovestibular Function fails to recapitulate fidelity: low The mouse does not reproduce the human maintenance failure. Instead of an anatomically normal ear that deteriorates, homozygotes have an ear that was never built correctly, and heterozygotes have no phenotype at all.
Limitations: Recessive lethality of the phenotype for modelling purposes: there is no mouse genotype corresponding to a human DFNA7 patient. The homozygous lesion is morphogenetic and prenatal, evident on paint-filled inner ears at E16.5, whereas human DFNA7 hearing loss frequently begins in adolescence or adulthood on an ear that imaging calls normal. Any inference from these mice about whether adult LMX1A restoration could help is therefore unsupported.
Show evidence (2 references)
PMID:23226461 REFUTE Model Organism
"Paint-filled inner ears at E16.5 revealed that mtl and bsd homozygotes lack endolymphatic ducts and semicircular canals and have short cochlear ducts."
A prenatal structural absence of major labyrinthine components, which is not the human DFNA7 lesion and refutes reading this model as one of postdevelopmental maintenance.
+ 1 more reference
Show evidence (1 reference)
PMID:23226461 SUPPORT Model Organism
"The characterization of these two new Lmx1a alleles highlights the critical role of this gene in the development of the cochlea and vestibular system."
The authors' own summary of what these alleles establish.
Lmx1a dreher null mouse
The classical Lmx1a functional null. Homozygotes lack the endolymphatic duct and have a poorly developed membranous labyrinth. The more informative finding is that the three primary otic fates are still specified but their boundaries are violated, with an expanded neurogenic domain and ectopic vestibular-like hair cells in the cochlear duct, which is what makes Lmx1a a selector gene rather than a differentiation factor. Later work on the same allele showed the stria vascularis fails to form: marginal and intermediate cell markers are absent, prospective intermediate cells migrate and then disappear, and no endocochlear potential is generated.
Species
Mouse
Genotype
Lmx1a dreher, homozygous functional null
Genes
LMX1A hgnc:6653 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns LMX1A (hgnc:6653). hgnc:6653 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:19540218
Pathograph links
LMX1A Haploinsufficiency fails to recapitulate fidelity: low Included because it is the model most often cited when LMX1A is discussed, and because being explicit about what it does not show is more useful than omitting it. The dreher null defines the gene's developmental job comprehensively. It does not model a heterozygous dosage reduction.
Limitations: Complete homozygous loss of function, against a human disease of one remaining functional allele. The phenotypes are of a kind absent from human DFNA7: no endocochlear potential, absent stria vascularis marker expression, ectopic vestibular-like hair cells in the cochlear duct. Quantitatively and qualitatively this is a different lesion, and citing it as the DFNA7 mechanism would overstate what heterozygous human alleles do.
Readouts
Endocochlear potential
Direction: ABOLISHED
Interpretation: Complete Lmx1a loss abolishes the endocochlear potential. No comparable measurement exists for a heterozygous allele in any species.
Show evidence (1 reference)
PMID:40109362 SUPPORT Model Organism
"Moreover, in the absence of Lmx1a expression, no endocochlear potential is observed."
The functional endpoint of strial failure in the homozygous null.
Stria vascularis marker expression
Direction: DECREASED
Interpretation: Marginal and intermediate cell identity markers are absent, showing that Lmx1a is required for strial cell differentiation and not only for gross morphogenesis.
Show evidence (1 reference)
PMID:40109362 SUPPORT Model Organism
"In the absence of Lmx1a, we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells."
The cell-type-specific molecular readout of strial failure.
Show evidence (1 reference)
PMID:19540218 REFUTE Model Organism
"In an Lmx1a functional null mutant, dreher (dr(J)/dr(J)), the inner ears lack a non-sensory structure, the endolymphatic duct, and the membranous labyrinth is poorly developed."
A structural developmental phenotype absent from human DFNA7, which is why the null is recorded as failing to recapitulate the human heterozygous mechanism.
Show evidence (2 references)
PMID:19540218 SUPPORT Model Organism
"Furthermore, aberrant and ectopic sensory organs are observed; most striking among these is vestibular-like hair cells located in the cochlear duct."
The boundary-violation phenotype that establishes Lmx1a's selector-gene role, and the clearest illustration of how different the null is from the human disease.
PMID:40109362 SUPPORT Model Organism
"The transcription factor Lmx1a is widely expressed during early inner ear development, and mice lacking Lmx1a expression exhibit fusion of cochlear and vestibular hair cells and fail to form the ductus reuniens and the endolymphatic sac."
The developmental scope of Lmx1a loss in the null, summarised by the same group.
{ }

Source YAML

click to show 
name: Autosomal Dominant Nonsyndromic Hearing Loss 7
category: Mendelian
creation_date: "2026-08-28T00:00:00Z"
synonyms:
- DFNA7
- autosomal dominant nonsyndromic deafness 7
- autosomal dominant nonsyndromic deafness type 7
- autosomal dominant deafness 7
- deafness, autosomal dominant 7
- LMX1A-related autosomal dominant nonsyndromic hearing loss
description: >-
  DFNA7 is the dominant, hearing-only phenotype produced by heterozygous variants in
  LMX1A, a LIM-homeodomain transcription factor. The gene is best known from mouse
  developmental genetics, where it acts as a selector gene that partitions the otic
  vesicle into neural, sensory and non-sensory territory and is required to build the
  endolymphatic duct, the semicircular canals and the stria vascularis.

  The point that organises this entry is that the human dominant disease is not a milder
  version of that developmental catastrophe. Homozygous null mice have grossly malformed
  inner ears and no endocochlear potential; heterozygous mice hear normally. Human
  heterozygotes, by contrast, are born with anatomically normal cochleae on imaging and
  then lose hearing over years or decades. The Dutch families in which DFNA7 was
  established were explicit about the inference this forces: one wild-type copy of LMX1A
  appears to be enough to build the ear but not enough to keep it working. Whatever
  DFNA7 is, it is a maintenance failure sitting downstream of a developmental
  transcription factor, and the mouse null is a model of the gene's job rather than a
  model of the disease.

  The molecular mechanism is haploinsufficiency, and this has been tested rather than
  assumed. Reporter assays across the reported allelic series show reduced transactivation
  for missense, nonsense and frameshift alleles alike; plasmid titration and transcript
  stability chase experiments specifically excluded a dominant-negative effect. Severity
  tracks the size of the transcriptional deficit, with the most transcriptionally damaging
  allele reported so far found in the one subject with congenital severe-to-profound
  deafness.

  Two clinical features recur often enough to be worth knowing at the bedside. Hearing
  loss in DFNA7 is characteristically asymmetric between the two ears, unusually so for a
  dominant nonsyndromic form, and roughly half of affected individuals have measurable
  vestibular dysfunction whether or not they complain of it. Intrafamilial variability is
  wide: within single families, onset ranges from infancy to mid-adulthood and severity
  from mild to profound on the same allele, so a mildly affected parent gives little
  prognostic information about an affected child.

  LMX1A is not exclusively dominant. A homozygous C-terminal missense variant has been
  reported in a consanguineous Pakistani family with severe-to-profound recessive hearing
  impairment, so the gene spans both inheritance modes. MONDO carries no separate term for
  that recessive phenotype, so it is curated here as a second inheritance block and a
  second genetic entry rather than being left uncovered.

  One caveat about the identity of this entry. DFNA7 is a locus, defined in 1996 by
  linkage in a large Norwegian family to a 22 cM interval on 1q21-q23, and MONDO's
  definition still reflects that: it names the material basis as variation in the
  chromosome region rather than as a gene. LMX1A sits at 1q23.3, inside that interval,
  but it was tied to dominant hearing loss 22 years later in unrelated Dutch families, and
  no report identifies an LMX1A variant in the founding Norwegian pedigree. The
  gene-to-locus assignment therefore rests on positional plausibility plus independent
  families, not on solving the original family.
disease_term:
  preferred_term: autosomal dominant nonsyndromic hearing loss 7
  term:
    id: MONDO:0011074
    label: autosomal dominant nonsyndromic hearing loss 7
parents:
- Autosomal Dominant Nonsyndromic Hearing Loss
inheritance:
- name: Autosomal dominant
  description: >-
    Heterozygous LMX1A variants segregating with hearing loss in multi-generation
    pedigrees, with de novo occurrence documented for at least two alleles. Penetrance
    appears high but expressivity is markedly variable within families.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
    explanation: The founding dominant families and the heterozygous state of the alleles.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding."
    explanation: >-
      A de novo dominant allele, which matters for counselling because an apparently
      isolated case does not exclude LMX1A.
  - reference: PMID:36519758
    reference_title: "A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This C-terminal frameshift mutation co-segregated with autosomal dominant (AD) NSHL in a four-generation Chinese family"
    explanation: Four-generation cosegregation of a truncating allele with dominant disease.
- name: Autosomal recessive
  description: >-
    A second, much rarer inheritance mode for the same gene. A homozygous C-terminal
    missense variant, p.Ile369Thr, was reported in a consanguineous Pakistani family with
    severe-to-profound hearing impairment. It is curated inside this entry rather than
    separately because MONDO has no distinct term for an LMX1A-related recessive
    nonsyndromic hearing loss, and because the two modes are mechanistically continuous:
    the recessive C-terminal residue interacts with homeodomain residue Val241, which is
    itself mutated in dominant families.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:29971487
    reference_title: "A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we used a homozygosity mapping and exome sequencing strategy to study a consanguineous Pakistani family with autosomal recessive severe-to-profound hearing impairment."
    explanation: The recessive pedigree and the mapping strategy that identified it.
  - reference: PMID:29971487
    reference_title: "A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results suggest that LMX1A is involved in both human autosomal recessive and dominant sensorineural hearing impairment."
    explanation: The authors' conclusion that the gene spans both inheritance modes.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variants in the LIM-homeodomain transcription factor LMX1A represent a rare yet critical etiology for autosomal dominant nonsyndromic hearing loss 7 (DFNA7) and less frequently, its autosomal recessive counterpart (ARNSHL)."
    explanation: >-
      Independent confirmation that the recessive counterpart exists and is the less common
      of the two, which is why it is a block within this entry rather than an entry of its
      own.
pathophysiology:
- name: LMX1A Haploinsufficiency
  description: >-
    A single functional LMX1A allele remains. The reported alleles are heterogeneous in
    kind, including homeodomain missense substitutions that weaken DNA binding, nonsense
    alleles that remove the homeodomain entirely, and C-terminal frameshifts that delete
    the helix mediating LIM2-domain interaction. What unites them is the direction of the
    effect on protein dosage rather than any shared structural lesion.

    That this is dosage insufficiency and not interference by the mutant protein has been
    tested directly. Plasmid titration and Actinomycin D transcript-chase experiments
    corroborated haploinsufficiency and excluded a dominant-negative effect, and an
    earlier study reached the same conclusion for a de novo homeodomain allele. The
    distinction matters therapeutically: a haploinsufficiency mechanism is in principle
    addressable by raising expression of the remaining allele, whereas a dominant-negative
    one is not.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  downstream:
  - target: Reduced Transactivation of LMX1A Target Genes
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, plasmid titration experiments and Actinomycin D chase assays functionally corroborated the haploinsufficiency mechanism and excluded the dominant-negative effect."
    explanation: >-
      The direct experimental test that separates haploinsufficiency from a
      dominant-negative mechanism.
  - reference: PMID:32840933
    reference_title: "Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Further, our dominant LMX1A variant exerted pathogenic effects via haploinsufficiency rather than dominant-negative effect."
    explanation: Independent replication of the haploinsufficiency conclusion on a different allele.
  - reference: PMID:35254497
    reference_title: "Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We also provide further evidence for haploinsufficiency as the pathogenic mechanism underlying LMX1A-related ADHL."
    explanation: A third independent group reaching the same mechanistic conclusion.
- name: Reduced Transactivation of LMX1A Target Genes
  description: >-
    LMX1A is a DNA-binding transcription factor, and every disease allele assayed so far
    reduces its ability to drive transcription of downstream targets in reporter systems.
    The structural routes differ. Homeodomain missense substitutions attenuate the
    protein-DNA interaction; a premature stop destroys the protein including the
    homeodomain; a C-terminal frameshift removes a helix required for LIM2-domain
    interaction and for protein-DNA binding, without triggering nonsense-mediated decay.

    The quantitative version of this node is what gives DFNA7 its genotype-phenotype
    correlation: the allele with the largest measured loss of transcriptional activity is
    the one found in congenital severe-to-profound deafness, while alleles with only
    moderately reduced activity are associated with later-onset progressive loss.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    modifier: DECREASED
  downstream:
  - target: Impaired Maintenance of Cochleovestibular Function
    causal_link_type: DIRECT
  - target: Cochlear Hair Cell Apoptosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:35711095
    reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Compared with the wild-type protein, all mutant LMX1A proteins had significantly reduced transactivation efficiency, indicating that the ability to elicit transcription of the downstream target genes of LMX1A was severely compromised."
    explanation: Reduced transactivation across four structurally different novel alleles.
  - reference: PMID:32840933
    reference_title: "Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Resultantly, p.Arg199Gly manifesting the most severe NSHL showed the biggest reduction of transcriptional activity in contrast with moderately reduced activity of p.Cys97Ser and p.Val241Leu associated with less severe progressive NSHL, proposing a genotype-phenotype correlation."
    explanation: >-
      The dose-response between measured transcriptional deficit and clinical severity,
      which is what makes this node quantitative rather than merely present or absent.
  - reference: PMID:35254497
    reference_title: "Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "and one family with a novel variant in LMX1A (c.686C>A; p.(Ala229Asp)) that impairs its transcriptional activity"
    explanation: A further allele independently shown to impair transcriptional activity.
  - reference: PMID:36519758
    reference_title: "A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In addition, electrophoresis mobility shift assay and luciferase assays have shown that the highly conserved C-terminal domain (amino acid 306-382) of the LMX1A was required for regulating the protein-DNA interaction and transactivation in vitro."
    explanation: >-
      Establishes that the C-terminus, not only the homeodomain, is needed for DNA binding
      and transactivation, which is why frameshift alleles distal to the homeodomain are
      pathogenic.
- name: Impaired Maintenance of Cochleovestibular Function
  description: >-
    The proposed human mechanism: reduced LMX1A dosage is compatible with building an
    anatomically normal inner ear but not with sustaining its function. The clinical
    observations behind this are that onset is typically late, the course is progressive,
    and computed tomography shows no cochleovestibular malformation in affected
    individuals.

    Two readings of this were offered in the original description and neither has been
    resolved. Either LMX1A has an ongoing postdevelopmental requirement in the
    cochleovestibular epithelium, or subtle developmental abnormalities below the
    resolution of clinical imaging set up a structure that degrades over time. The
    distinction is not academic: only the first predicts that raising LMX1A expression in
    an adult ear could help.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  - preferred_term: vestibular hair cell
    term:
      id: CL:0000609
      label: vestibular hair cell
  biological_processes:
  - preferred_term: detection of mechanical stimulus involved in sensory perception of sound
    term:
      id: GO:0050910
      label: detection of mechanical stimulus involved in sensory perception of sound
    modifier: DECREASED
  - preferred_term: detection of mechanical stimulus involved in equilibrioception
    term:
      id: GO:0050973
      label: detection of mechanical stimulus involved in equilibrioception
    modifier: DECREASED
  downstream:
  - target: Progressive Sensorineural Hearing Impairment
    causal_link_type: DIRECT
  - target: Vestibular Dysfunction
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We propose that a single LMX1A wild-type copy is sufficient for normal development but insufficient for maintenance of cochleovestibular function."
    explanation: The maintenance hypothesis stated by the group that established the disease.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The late-onset progressive phenotype and the absence of cochleovestibular malformations on computed tomography scans indicate that heterozygous defects of LMX1A do not result in severe developmental abnormalities in humans."
    explanation: >-
      The imaging and natural-history observations that rule out a gross developmental
      lesion in human heterozygotes.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families."
    explanation: >-
      Graded PARTIAL because it is the authors' own competing explanation for the same
      data. Curated deliberately so the node is not read as a settled postdevelopmental
      maintenance claim.
- name: Cochlear Hair Cell Apoptosis
  description: >-
    A candidate cellular endpoint, supported only in a cell line so far. In HEI-OC1
    auditory cells, the C-terminal domain of LMX1A was shown to be important for mediating
    apoptosis, and cells carrying the heterozygous frameshift variant upregulated several
    hearing-loss-associated genes at the transcript level. This is included because it is
    the only cellular death mechanism yet proposed for DFNA7, and flagged as in vitro
    because no human or mouse cochlear histology exists for a heterozygous LMX1A allele.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: cochlea auditory hair cell
    term:
      id: CL:4023120
      label: cochlea auditory hair cell
  downstream:
  - target: Progressive Sensorineural Hearing Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:36519758
    reference_title: "A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, apoptosis assays suggested that the C-terminal domain of the LMX1A was important for mediating apoptosis in the cochlear hair cells."
    explanation: >-
      Graded PARTIAL because the assay establishes a domain requirement in a cell line,
      not that hair cell apoptosis occurs in DFNA7 patients.
  - reference: PMID:36519758
    reference_title: "A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We also found that the embryonic cells carrying with the heterozygous variant significantly expressed several upregulated HL-associated genes at transcriptional level."
    explanation: >-
      A transcriptional consequence of the heterozygous allele in cells; supportive of a
      cell-autonomous effect but not of apoptosis in patient tissue.
phenotypes:
- name: Progressive Sensorineural Hearing Impairment
  category: Auditory
  description: >-
    Bilateral sensorineural hearing loss that worsens over time. Progression is the
    defining feature and it is what the maintenance mechanism predicts.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Progressive sensorineural hearing impairment
    term:
      id: HP:0000408
      label: Progressive sensorineural hearing impairment
  evidence:
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
    explanation: Progressive nonsyndromic hearing impairment in the founding families.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cosegregating with progressive and asymmetric sensorineural hearing loss"
    explanation: Progression confirmed in an independent three-generation family.
- name: Asymmetric Sensorineural Hearing Loss
  category: Auditory
  description: >-
    Hearing thresholds differ appreciably between the two ears. This was found in all
    probands and most affected individuals of a five-family DFNA7 series, and is unusual
    enough for a dominant nonsyndromic form that the authors proposed LMX1A as a candidate
    gene to consider specifically when asymmetric dominant hearing loss is encountered.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Asymmetric sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:35711095
    reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied."
    explanation: The primary observation, with its own caveat about varying extent.
  - reference: PMID:35711095
    reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss."
    explanation: The diagnostic implication the authors draw.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cosegregating with progressive and asymmetric sensorineural hearing loss"
    explanation: Independent replication of asymmetry in a Chinese family.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subject IV:2 of family W15-0551 and subject II:2 of family 63136 displayed asymmetric HI, whereas the other affected individuals demonstrated symmetric HI."
    explanation: >-
      Graded PARTIAL because it is a counterweight rather than support. In the founding
      Dutch families only two individuals were asymmetric and the rest were symmetric,
      which is the observation that keeps this phenotype at FREQUENT rather than
      VERY_FREQUENT and makes the near-universal Korean figure look ascertainment
      dependent.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individual I: 2 developed progressive, symmetric high‐frequency SNHL in his early 30s."
    explanation: >-
      Graded PARTIAL for the same reason: a symmetric individual inside the family whose
      report is cited above as replicating asymmetry, so the two are not in conflict about
      the family, only about how universal the feature is.
  - reference: PMID:36140227
    reference_title: "Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Asymmetric hearing loss (interaural difference > 15dB) was identified in five of the nine patients."
    explanation: >-
      The only reported count with an explicit threshold and denominator: five of nine, or
      about 56 percent, which is what puts this phenotype in the FREQUENT band rather than
      the VERY_FREQUENT one.
  - reference: PMID:36140227
    reference_title: "Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Indeed, most LMX1A-related DFNA7 patients display audiologic asymmetry to varying degrees and a gradual progression of hearing loss."
    explanation: >-
      The qualitative claim alongside the count, and the phrase that matters is "to varying
      degrees" - asymmetry in DFNA7 is a spectrum measured against a threshold, not a
      categorical feature.
  notes: >-
    HPO has no term for asymmetric hearing impairment, so phenotype_term is bound to the
    accurate parent HP:0000407 and the asymmetry is carried by preferred_term. Binding a
    narrower but wrong term would be worse than this.

    Frequency is FREQUENT rather than VERY_FREQUENT, and the spread across sources is why.
    Asymmetry was universal among probands in the Korean five-family series but the
    founding Dutch families were mostly symmetric, two individuals in the Chinese family
    are described as symmetric, and the two-centre Korean series that counted with an
    explicit threshold found it in five of nine patients. The Korean cohort is the one that looked for asymmetry deliberately,
    which makes it the most sensitive series and also the most likely to be ascertainment
    dependent; grading to it alone would overstate the phenotype in the disease as a whole.
- name: Downsloping High-Frequency Audiogram Configuration
  category: Auditory
  description: >-
    The characteristic audiogram shape. Across the founding Dutch families the overall
    configuration was downsloping, with severity ranging from mild to profound, and
    individual members of the later Chinese family are described with high-frequency loss
    specifically. The shape matters diagnostically because it is what makes DFNA7 in an
    adult resemble presbycusis or noise damage.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: High-frequency sensorineural hearing impairment
    term:
      id: HP:0001757
      label: High-frequency sensorineural hearing impairment
  evidence:
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected subjects had mild to profound HI with overall a downsloping audiogram configuration"
    explanation: The audiogram configuration across the founding families, with its severity range.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individual II: 2 exhibited high‐frequency SNHL with no documented history of exposure to known ototoxic agents."
    explanation: >-
      High-frequency loss in an independent family, with ototoxic exposure explicitly
      excluded, which matters because the same audiogram shape is the signature of
      acquired causes.
  notes: >-
    Bound to HP:0001757 for the high-frequency component, matching the DFNA41 and DFNB103
    entries curated in the same batch. HPO has no term for a downsloping audiogram
    configuration as such, so the shape is carried by the phenotype name and description.
- name: Vestibular Dysfunction
  category: Vestibular
  description: >-
    Measurable vestibular impairment in roughly half of affected individuals, with
    symptoms in those affected. It is easy to miss because it is not what brings patients
    to attention, and because the corresponding mouse phenotype only appears in
    homozygotes.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal vestibular function
    term:
      id: HP:0001751
      label: Abnormal vestibular function
  evidence:
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About half of the affected individuals displayed vestibular dysfunction and experienced symptoms thereof."
    explanation: Frequency and symptomatic status of vestibular involvement in the founding families.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cVEMPs showed no responses up to 100 dBnHL in both subjects, indicating dysfunction of the saccule."
    explanation: >-
      Localises the deficit to the saccule rather than leaving it at organ level, which is
      the kind of detail that distinguishes a measured vestibular phenotype from a reported
      symptom.
- name: Congenital Severe-to-Profound Sensorineural Hearing Impairment
  category: Auditory
  description: >-
    The severe end of the DFNA7 spectrum. It is uncommon, but it exists and it is not
    random: the one subject reported with congenital severe-to-profound deafness carried
    the allele with the largest measured reduction in transcriptional activity, and
    profound congenital deafness at birth was also seen in the four-generation family
    carrying a C-terminal frameshift.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Congenital sensorineural hearing impairment
    term:
      id: HP:0008527
      label: Congenital sensorineural hearing impairment
  evidence:
  - reference: PMID:32840933
    reference_title: "Novel genotype-phenotype correlation of functionally characterized LMX1A variants linked to sensorineural hearing loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identification of a de novo, heterozygous, missense variant (c.595A > G; p.Arg199Gly) located in the homeodomain of LMX1A in a subject with congenital severe-to-profound deafness through Exome sequencing"
    explanation: The congenital severe-to-profound case and the allele responsible.
  - reference: PMID:36519758
    reference_title: "A novel frameshift variant of LMX1A that leads to autosomal dominant non-syndromic sensorineural hearing loss: functional characterization of the C-terminal domain in LMX1A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this family, the affected individuals exhibited the variable auditory phenotypes ranging from profound congenital deafness at birth or to mild/moderate HL in adulthood."
    explanation: >-
      Congenital profound deafness at one end of a single family's range, which is also
      the clearest statement of how wide intrafamilial variability is.
- name: Postlingual Sensorineural Hearing Impairment
  category: Auditory
  description: >-
    The more usual presentation: hearing that is adequate in early life and declines
    afterwards, in some individuals not until mid-adulthood.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Postlingual sensorineural hearing impairment
    term:
      id: HP:0008596
      label: Postlingual sensorineural hearing impairment
  evidence:
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
    explanation: >-
      Documents onset extending to mid-adulthood, and the intrafamilial spread that makes
      prognosis from an affected relative unreliable.
  - reference: PMID:41078281
    reference_title: "A Novel Missense Variant in LMX1A Leads to Autosomal Dominant Nonsyndromic Hearing Loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic testing revealed a variant of uncertain significance (p.Val241Ala) in LMX1A in a 56-year-old male with hearing loss since adolescence and his 12-year-old son, who failed newborn hearing screening."
    explanation: >-
      A father-son pair spanning the range within one allele, adolescent onset in one and
      a failed newborn screen in the other.
prevalence:
- population: Worldwide, published cases
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Fewer than ten pathogenic LMX1A variants had been reported as of 2026.
  evidence:
  - reference: PMID:41078281
    reference_title: "A Novel Missense Variant in LMX1A Leads to Autosomal Dominant Nonsyndromic Hearing Loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hereditary nonsyndromic hearing loss (NSHL) is a prevalent entity associated with over 150 known causative genes, including LMX1A, which has fewer than 10 reported pathogenic variants."
    explanation: The size of the reported allelic series.
genetic:
- name: LMX1A
  notes: >-
    LMX1A encodes a LIM-homeodomain transcription factor with two N-terminal LIM domains
    that mediate protein-protein interactions, a central homeodomain that binds DNA, and a
    C-terminal region required for the protein-DNA interaction and for interaction with
    the LIM2 domain. Disease alleles are distributed across all three regions. Val241 in
    the homeodomain has now been hit by at least two different substitutions in unrelated
    families, which has been suggested as a possible mutational hotspot.
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  case_fractions:
  - population: Korean hearing loss probands undergoing exome sequencing
    case_fraction_percent: 0.7
    cohort_size: 728
    notes: >-
      Five DFNA7 families among 728 probands sequenced regardless of audiological
      phenotype. This is a share of an ascertained hearing loss cohort, not a population
      prevalence, and it is the only quantitative figure available for how often LMX1A
      explains hereditary hearing loss.
    evidence:
    - reference: PMID:35711095
      reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Five LMX1A -associated DFNA7 families (approximately 0.7%), the pedigrees of whom indicated autosomal-dominant hearing loss, were identified, and segregation was studied using Sanger sequencing."
      explanation: The yield figure and its denominator.
    - reference: PMID:35711095
      reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Among 728 probands of which genomic DNA went through exome sequencing regardless of any specific audiologic phenotypes, probands for which exome sequencing was performed and a causative LMX1A variant was found were all included."
      explanation: >-
        The ascertainment, which matters for interpreting the fraction: probands were
        sequenced regardless of audiological phenotype, so the denominator is not enriched
        for the asymmetric presentation LMX1A causes.
  evidence:
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variants in the LIM-homeodomain transcription factor LMX1A represent a rare yet critical etiology for autosomal dominant nonsyndromic hearing loss 7 (DFNA7) and less frequently, its autosomal recessive counterpart (ARNSHL)."
    explanation: The gene-disease relationship, and the existence of a recessive counterpart.
  - reference: PMID:41078281
    reference_title: "A Novel Missense Variant in LMX1A Leads to Autosomal Dominant Nonsyndromic Hearing Loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other pathogenic missense variants have previously been reported at the same Val241 site, suggesting that this location may be a hotspot for pathogenic variants contributing to NSHL, although further research is needed."
    explanation: >-
      Graded PARTIAL because the authors explicitly hedge the hotspot claim; two
      substitutions at one residue is suggestive, not established.
  - reference: PMID:35711095
    reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, Arg208*-induced premature termination of translation destroyed the structure of the LMX1A protein, including the DNA-binding homeodomain, and p.Gln297Thrfs*41 led to the loss of the C-terminal helix involved in LIM2 domain interaction."
    explanation: >-
      The structural consequences of the truncating alleles, which is why alleles across
      the whole gene converge on reduced dosage.
  - reference: PMID:29971487
    reference_title: "A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results suggest that LMX1A is involved in both human autosomal recessive and dominant sensorineural hearing impairment."
    explanation: >-
      Graded PARTIAL because it establishes something about the gene rather than about
      DFNA7: LMX1A is not exclusively dominant, so a homozygous LMX1A finding does not by
      itself place a family in this entry.
- name: LMX1A homozygous C-terminal missense allele
  notes: >-
    The recessive arm of the LMX1A allelic series. A homozygous p.Ile369Thr variant was
    reported in a consanguineous Pakistani family with autosomal recessive
    severe-to-profound hearing impairment. It is curated inside this entry, alongside the
    recessive inheritance block, because MONDO has no separate term for an LMX1A-related
    recessive nonsyndromic hearing loss. Mechanistically it is continuous with the dominant
    disease rather than parallel to it: the substituted C-terminal residue interacts with
    homeodomain residue Val241, which is itself mutated in dominant families.
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  evidence:
  - reference: PMID:29971487
    reference_title: "A variant in LMX1A causes autosomal recessive severe-to-profound hearing impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The p.Ile369Thr variant disrupts several C-terminal and homeodomain residue interactions, including an interaction with homeodomain residue p.Val241 that was previously found to be involved in autosomal dominant progressive HI."
    explanation: >-
      The structural link between the recessive C-terminal allele and the dominant
      homeodomain residue, which is why the two inheritance modes are not unrelated
      accidents of the same gene.
diagnosis:
- name: Consider LMX1A when dominant hearing loss is asymmetric
  description: >-
    DFNA7 is reached by gene-panel or exome sequencing rather than by any specific
    audiological test, but asymmetry is a usable prompt. Asymmetric thresholds in a
    dominant pedigree would ordinarily suggest an acquired or structural cause; in this
    disorder they are the rule. Imaging is typically normal, so a normal CT does not
    argue against the diagnosis, and in one severely affected proband high-resolution
    imaging showed bilateral cochlear aperture stenosis, so an abnormal scan does not
    argue against it either.
  evidence:
  - reference: PMID:35711095
    reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the first time, we suggest that LMX1A is one of the candidate genes which, if altered, could be associated with dominantly inherited asymmetric hearing loss."
    explanation: The authors' explicit diagnostic recommendation.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "High-resolution imaging revealed bilateral cochlear aperture stenosis (CAS) in the severely affected proband."
    explanation: >-
      Graded PARTIAL: a single severely affected proband with an imaging abnormality, in a
      disorder otherwise characterised by normal scans. Recorded so a curator does not
      treat normal imaging as an entry criterion.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "recommend screening for HI in subjects with mono-allelic loss of LMX1A."
    explanation: >-
      The reverse direction of ascertainment, and the practically useful one: someone found
      to have lost one LMX1A copy for another reason, such as a chromosomal deletion,
      should have their hearing checked.
treatments:
- name: Hearing Amplification
  description: >-
    Hearing aids, fitted to the audiogram. There is no disease-modifying therapy for
    DFNA7. Asymmetric thresholds complicate fitting in a way they do not for symmetric
    dominant forms, and the wide intrafamilial variability means timing has to be
    individual rather than inherited from an affected parent's course.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: hearing aid fitting
  evidence:
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She was fitted with bilateral hearing aids, achieving near‐normal speech perception."
    explanation: >-
      Amplification in a molecularly confirmed DFNA7 patient, with the outcome stated.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individual II: 1 developed symmetric, bilateral severe SNHL across frequencies in early childhood and uses bilateral hearing aids."
    explanation: >-
      A second aided individual in the same family, at the severe end of the range, which
      is what makes amplification the standing management rather than a single case.
  notes: >-
    No NCIT clinical-action term exists for hearing-aid fitting that is reachable from
    NCIT:C25218, so treatment_term is deliberately left unbound with a free-text
    preferred_term.

    Speech-language rehabilitation has no DFNA7-specific report and is not curated.
- name: Cochlear Implantation
  description: >-
    Cochlear implantation for an ear that has progressed to profound loss. The reported
    DFNA7 experience is one patient: her left ear deteriorated to profound loss while the
    asymmetry between the ears persisted, she underwent unilateral implantation, and her
    speech perception improved significantly at three and six months. Follow-up beyond six
    months is not reported for her.

    Asymmetry is what makes implantation a live question earlier in DFNA7 than in a
    symmetric dominant loss: one ear can reach implantable thresholds while the other is
    still aidable, so the decision is per-ear rather than per-patient.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: cochlear implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:36140227
    reference_title: "Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient eventually underwent unilateral CI, with significant improvement in her speech perception scores 3 and 6 months postoperatively (Figure 2c)."
    explanation: The implantation and its short-term speech outcome in a DFNA7 patient.
  - reference: PMID:36140227
    reference_title: "Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In one patient (SB727), hearing deteriorated to profound hearing loss in her left ear and the asymmetric hearing loss remained."
    explanation: >-
      The clinical situation that led to implantation, and the reason it was unilateral:
      one ear reached profound loss while the asymmetry persisted.
  - reference: PMID:36140227
    reference_title: "Genetic Load of Alternations of Transcription Factor Genes in Non-Syndromic Deafness and the Associated Clinical Phenotypes: Experience from Two Tertiary Referral Centers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results provide evidence for favorable CI outcomes in patients with LMX1A-related DFNA7."
    explanation: >-
      Graded PARTIAL because the authors' generalisation rests on a single implanted DFNA7
      patient in this series. The direction is favourable; the sample is one.
  notes: >-
    treatment_term is bound to NCIT:C15329 Surgical Procedure. NCIT's cochlear implant
    concepts (for example NCIT:C157820 Cochlear Implant) are device terms and are not
    reachable from NCIT:C25218 Clinical Intervention or Procedure, so they fail
    TreatmentActionTerm validation; the accurate broader action term is used rather than a
    forced narrower binding. therapeutic_modality is DEVICE rather than SURGERY because the
    therapeutic platform is the implant, with surgery as the route of delivery.

    A caution for anyone mining PMID:36140227 further: it reports four transcription-factor
    genes side by side, and its implantation results are not all LMX1A. The three
    implantees with favourable one-year K-CID, PB and spondee scores are POU4F3 patients,
    the middle-ear-implantation case is POU4F3, and the patient implanted at 80 whose K-CID
    rose from 18 to 60 percent at two years carries an EYA4 variant. Only patient SB727 is
    LMX1A, and only her results are curated here.
- name: Genetic Counselling with Audiologic Surveillance
  description: >-
    Counselling carries an unusual amount of weight here. Onset within a single family
    spans infancy to mid-adulthood on one allele, so an at-risk child cannot be reassured
    by a mildly affected parent, and a de novo allele has been documented, so an isolated
    case does not exclude the gene. Serial audiometry rather than a single normal test is
    what detects the progressive component.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
    explanation: The intrafamilial spread that makes prediction from a relative's course unsafe.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One variant, c.721G > C (p.Val241Leu), occurred de novo and is predicted to affect the homeodomain of LMX1A, which is essential for DNA binding."
    explanation: Documented de novo occurrence, which is what makes a negative family history uninformative.
animal_models:
- name: Lmx1a mutanlallemand and Belly Spot and Deafness mice
  species: Mouse
  genotype: Lmx1a mtl and Lmx1a bsd, homozygous
  publication: PMID:23226461
  description: >-
    Two spontaneous Lmx1a alleles: mtl, a 3' splice-site point mutation in exon 4 producing
    a truncated protein affecting the homeodomain, and bsd, a genomic deletion removing
    exon 3 and truncating within the LIM2 domain. Both reduce Lmx1a transcript levels.
    Homozygotes are deaf by auditory brainstem response, circle and toss their heads, and
    lack endolymphatic ducts and semicircular canals with short cochlear ducts. Hmx2/3 and
    Pax2 expression are down-regulated, placing Lmx1a upstream of those factors in early
    inner ear morphogenesis.
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  modeled_mechanisms:
  - target: Reduced Transactivation of LMX1A Target Genes
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      These alleles establish in vivo what the human reporter assays measure in vitro:
      truncating Lmx1a lesions reduce transcript levels and reduce expression of
      downstream targets. That is the node being modelled, and it is modelled well.
    limitations: >-
      The relationship to DFNA7 stops there. Both alleles are recessive in the mouse.
      Heterozygous and wild-type littermates have normal hearing, so this system contains
      no animal in the genetic state that causes human DFNA7. The homozygous phenotype is
      a gross developmental malformation of the membranous labyrinth, which is precisely
      what human heterozygotes do not have on imaging. Reading these mice as a model of
      DFNA7 would invert the disease mechanism from maintenance failure to failed
      morphogenesis.
    readouts:
    - name: Hmx2/Hmx3 and Pax2 expression in the developing otocyst
      target: Reduced Transactivation of LMX1A Target Genes
      direction: DECREASED
      interpretation: >-
        Downstream transcriptional targets fall when Lmx1a is truncated, the in vivo
        counterpart of the reduced transactivation measured for human alleles.
      evidence:
      - reference: PMID:23226461
        reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Hmx2/3 and Pax2 expression are also down-regulated in mtl and bsd mutants, suggesting a role of Lmx1a upstream of these transcription factors in early inner ear morphogenesis."
        explanation: The measured transcriptional consequence of Lmx1a truncation in vivo.
    - name: Auditory brainstem response by genotype
      target: Reduced Transactivation of LMX1A Target Genes
      direction: UNCHANGED
      interpretation: >-
        Deliberately recorded as unchanged, because the informative result here is the
        negative one: heterozygotes hear normally, so mouse Lmx1a dosage does not
        reproduce the human dominant phenotype.
      evidence:
      - reference: PMID:23226461
        reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
        explanation: >-
          The genotype-phenotype split in the mouse, which is the basis for treating the
          model as informative about the gene rather than about the dominant disease.
    evidence:
    - reference: PMID:23226461
      reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Both mutations lead to a truncated LMX1A protein affecting the homeodomain (mtl) or LIM2-domain (bsd), which is critical for LMX1A protein function."
      explanation: >-
        The molecular lesions, which are of the same structural classes as human DFNA7
        alleles and so make the model informative for the transcriptional node.
  - target: Impaired Maintenance of Cochleovestibular Function
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      The mouse does not reproduce the human maintenance failure. Instead of an
      anatomically normal ear that deteriorates, homozygotes have an ear that was never
      built correctly, and heterozygotes have no phenotype at all.
    limitations: >-
      Recessive lethality of the phenotype for modelling purposes: there is no mouse
      genotype corresponding to a human DFNA7 patient. The homozygous lesion is
      morphogenetic and prenatal, evident on paint-filled inner ears at E16.5, whereas
      human DFNA7 hearing loss frequently begins in adolescence or adulthood on an ear
      that imaging calls normal. Any inference from these mice about whether adult LMX1A
      restoration could help is therefore unsupported.
    evidence:
    - reference: PMID:23226461
      reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: "Paint-filled inner ears at E16.5 revealed that mtl and bsd homozygotes lack endolymphatic ducts and semicircular canals and have short cochlear ducts."
      explanation: >-
        A prenatal structural absence of major labyrinthine components, which is not the
        human DFNA7 lesion and refutes reading this model as one of postdevelopmental
        maintenance.
    - reference: PMID:23226461
      reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: "The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
      explanation: >-
        Mouse heterozygotes are unaffected, so the genetic state that defines DFNA7
        produces no auditory phenotype in this species.
  evidence:
  - reference: PMID:23226461
    reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The characterization of these two new Lmx1a alleles highlights the critical role of this gene in the development of the cochlea and vestibular system."
    explanation: The authors' own summary of what these alleles establish.
- name: Lmx1a dreher null mouse
  species: Mouse
  genotype: Lmx1a dreher, homozygous functional null
  publication: PMID:19540218
  description: >-
    The classical Lmx1a functional null. Homozygotes lack the endolymphatic duct and have
    a poorly developed membranous labyrinth. The more informative finding is that the
    three primary otic fates are still specified but their boundaries are violated, with
    an expanded neurogenic domain and ectopic vestibular-like hair cells in the cochlear
    duct, which is what makes Lmx1a a selector gene rather than a differentiation factor.
    Later work on the same allele showed the stria vascularis fails to form: marginal and
    intermediate cell markers are absent, prospective intermediate cells migrate and then
    disappear, and no endocochlear potential is generated.
  genes:
  - preferred_term: LMX1A
    term:
      id: hgnc:6653
      label: LMX1A
  modeled_mechanisms:
  - target: LMX1A Haploinsufficiency
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      Included because it is the model most often cited when LMX1A is discussed, and
      because being explicit about what it does not show is more useful than omitting it.
      The dreher null defines the gene's developmental job comprehensively. It does not
      model a heterozygous dosage reduction.
    limitations: >-
      Complete homozygous loss of function, against a human disease of one remaining
      functional allele. The phenotypes are of a kind absent from human DFNA7: no
      endocochlear potential, absent stria vascularis marker expression, ectopic
      vestibular-like hair cells in the cochlear duct. Quantitatively and qualitatively
      this is a different lesion, and citing it as the DFNA7 mechanism would overstate
      what heterozygous human alleles do.
    readouts:
    - name: Endocochlear potential
      target: LMX1A Haploinsufficiency
      direction: ABOLISHED
      interpretation: >-
        Complete Lmx1a loss abolishes the endocochlear potential. No comparable
        measurement exists for a heterozygous allele in any species.
      evidence:
      - reference: PMID:40109362
        reference_title: "Lmx1a is essential for marginal cell differentiation and stria vascularis formation."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Moreover, in the absence of Lmx1a expression, no endocochlear potential is observed."
        explanation: The functional endpoint of strial failure in the homozygous null.
    - name: Stria vascularis marker expression
      target: LMX1A Haploinsufficiency
      direction: DECREASED
      interpretation: >-
        Marginal and intermediate cell identity markers are absent, showing that Lmx1a is
        required for strial cell differentiation and not only for gross morphogenesis.
      evidence:
      - reference: PMID:40109362
        reference_title: "Lmx1a is essential for marginal cell differentiation and stria vascularis formation."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "In the absence of Lmx1a, we observe a lack of proteins specific to the stria vascularis, such as BSND and KCNQ1 in marginal cells and CD44 in intermediate cells."
        explanation: The cell-type-specific molecular readout of strial failure.
    evidence:
    - reference: PMID:19540218
      reference_title: "Lmx1a maintains proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: "In an Lmx1a functional null mutant, dreher (dr(J)/dr(J)), the inner ears lack a non-sensory structure, the endolymphatic duct, and the membranous labyrinth is poorly developed."
      explanation: >-
        A structural developmental phenotype absent from human DFNA7, which is why the
        null is recorded as failing to recapitulate the human heterozygous mechanism.
  evidence:
  - reference: PMID:19540218
    reference_title: "Lmx1a maintains proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Furthermore, aberrant and ectopic sensory organs are observed; most striking among these is vestibular-like hair cells located in the cochlear duct."
    explanation: >-
      The boundary-violation phenotype that establishes Lmx1a's selector-gene role, and
      the clearest illustration of how different the null is from the human disease.
  - reference: PMID:40109362
    reference_title: "Lmx1a is essential for marginal cell differentiation and stria vascularis formation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The transcription factor Lmx1a is widely expressed during early inner ear development, and mice lacking Lmx1a expression exhibit fusion of cochlear and vestibular hair cells and fail to form the ductus reuniens and the endolymphatic sac."
    explanation: The developmental scope of Lmx1a loss in the null, summarised by the same group.
discussions:
- discussion_id: lmx1a_dominant_model_gap
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Every Lmx1a animal model of hearing loss is a homozygous null with a malformed inner
    ear, while DFNA7 is a heterozygous, anatomically normal ear that deteriorates. Does
    mouse Lmx1a heterozygosity really produce no auditory phenotype, or has it never been
    looked for with sufficiently sensitive or sufficiently aged measurements?
  attaches_to:
  - pathophysiology#Impaired Maintenance of Cochleovestibular Function
  - animal_models#Mouse
  rationale: >-
    This is the central translational problem for DFNA7 and it is a mismatch rather than
    an absence of evidence. Three independent Lmx1a alleles have been characterised in
    mice and all report that heterozygotes hear normally, so the negative result is
    reproducible. But the reported ABR comparisons are made in young animals in studies
    designed around the homozygous phenotype, whereas the human disease is late-onset and
    progressive and in some individuals does not declare itself until mid-adulthood. A
    mouse tested at a few weeks old is not the right test of a phenotype whose human
    equivalent takes decades.

    The consequence is that the mechanistic claim this entry rests on, that one LMX1A copy
    builds an ear but cannot maintain it, has never been tested in an animal. So the
    competing developmental explanation offered in the original human description, that
    imaging-invisible developmental abnormalities set up later decline, remains equally
    live. Aged heterozygous Lmx1a mice with serial ABR and DPOAE, and cochlear histology
    at the end of that series, would separate the two, and a knock-in of a human
    homeodomain allele would be a stronger test than heterozygous null because human
    alleles include missense substitutions with residual activity rather than clean
    deletions.
  evidence:
  - reference: PMID:23226461
    reference_title: "Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The analysis of auditory brainstem responses (ABR) showed that mtl and bsd homozygotes are deaf, whereas heterozygous and wildtype littermates have normal hearing."
    explanation: >-
      The mismatch itself: the genotype that causes human DFNA7 causes no measured
      auditory phenotype in the mouse.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although Lmx1a mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic features were present in the participating subjects of either family."
    explanation: >-
      The mismatch extends beyond the ear. Mouse Lmx1a mutants are syndromic across
      several organ systems; human LMX1A heterozygotes are not, so mouse extra-auditory
      phenotypes should not be used to predict human ones.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternatively, minor cochleovestibular developmental abnormalities could eventually lead to the progressive phenotype seen in the families."
    explanation: >-
      The competing developmental explanation that the missing animal experiment would
      test, stated by the authors as an explicit alternative to the maintenance reading.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "However, the absence of an HI phenotype in mice heterozygous for loss of function variants of Lmx1a is not supportive of haploinsufficiency as the disease mechanism."
    explanation: >-
      The sharpest statement of the mismatch, and it cuts against this entry's own
      mechanism. In 2018 the normal hearing of heterozygous mice was read as evidence
      against haploinsufficiency. Curated as REFUTE for that reason rather than softened.
      Later functional work resolved the mechanism in favour of haploinsufficiency on
      human alleles, with dominant-negative action excluded experimentally, so the argument
      no longer stands as an objection - but the mouse observation it rests on has never
      been explained, and that unexplained residue is precisely this gap.
  proposed_experiments:
  - experiment_id: exp_dfna7_aged_heterozygous_lmx1a_abr
    name: Aged heterozygous Lmx1a mouse auditory phenotyping
    description: >-
      Serial ABR and DPOAE in heterozygous Lmx1a mice through to old age, with cochlear
      and vestibular histology at endpoint, compared against wild-type littermates.
      Powered for a progressive threshold shift rather than for a categorical deaf or
      hearing call.
    would_support:
    - pathophysiology#Impaired Maintenance of Cochleovestibular Function
    supporting_outcome:
    - >-
      Heterozygotes show normal thresholds in early adulthood and a progressive
      age-dependent threshold elevation with hair cell or strial degeneration on
      endpoint histology.
    would_refute:
    - pathophysiology#Impaired Maintenance of Cochleovestibular Function
    refuting_outcome:
    - >-
      Heterozygotes remain audiometrically and histologically indistinguishable from
      wild-type littermates into old age, which would place the human mechanism outside
      simple mouse gene dosage and favour either the subtle-developmental explanation or
      a human-specific requirement.
- discussion_id: lmx1a_asymmetry_mechanism
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why is DFNA7 hearing loss asymmetric? What makes a cell-autonomous transcription
    factor dosage deficit, present equally in both ears, produce different thresholds on
    the two sides?
  attaches_to:
  - phenotypes#Asymmetric Sensorineural Hearing Loss
  - pathophysiology#Impaired Maintenance of Cochleovestibular Function
  rationale: >-
    Asymmetry is the most distinctive clinical feature of DFNA7 and nothing in the curated
    mechanism explains it. A germline heterozygous variant is present in both cochleae at
    the same dosage, so a purely dose-dependent maintenance failure predicts symmetric
    decline. Asymmetry implies that the deficit is permissive rather than deterministic,
    with something stochastic or environmental deciding how fast each ear declines, but
    what that something is has not been investigated.

    This is not idle. If a second, modifiable factor determines which ear declines first,
    it is a therapeutic target that the transcription factor itself is not; and if
    asymmetry is instead stochastic clonal drift in a maintenance process, that argues
    the window for intervention is set per ear rather than per patient. Nobody has
    reported longitudinal audiometry designed to distinguish these, nor tested whether the
    more-affected ear is predicted by noise history, otologic history or side dominance.
  evidence:
  - reference: PMID:35711095
    reference_title: "Novel Molecular Genetic Etiology of Asymmetric Hearing Loss: Autosomal-Dominant LMX1A Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is important to note that asymmetric hearing loss was identified in all probands and most affected individuals, although the extent of asymmetry varied."
    explanation: >-
      Establishes the phenomenon as near-universal in the series while explicitly noting
      that its degree varies, which is the variability the gap is about.
  - reference: PMID:42253511
    reference_title: "A Novel LMX1A Frameshift Variant Underlies Familial Phenotypic Heterogeneity in DFNA7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations exhibited significant intrafamilial phenotypic variability, with hearing loss (HL) severity ranging from mild to profound, and onset varying from infancy to mid-adulthood."
    explanation: >-
      Between-individual variability on one allele within one family, the same puzzle as
      between-ear asymmetry seen at a different scale, and equally unexplained by dosage.
- discussion_id: dfna7_locus_to_gene_assignment
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does the founding Norwegian DFNA7 family actually carry an LMX1A variant? The locus
    and the gene were established 22 years apart in different populations, and no report
    connects them in the original pedigree.
  attaches_to:
  - disease#Autosomal Dominant Nonsyndromic Hearing Loss 7
  - genetic#LMX1A
  rationale: >-
    DFNA7 is a locus name, not a gene name. It was defined in 1996 by linkage in a large
    Norwegian family with progressive high-tone hearing loss to a 22 cM interval between
    D1S104 and D1S466 on 1q21-q23, and the paper noted that the region contained several
    attractive candidate genes. MONDO's definition of MONDO:0011074 still describes the
    material basis as variation in that chromosome region rather than as a gene.

    LMX1A lies at 1q23.3, inside the interval, and heterozygous LMX1A variants were shown
    to cause dominant progressive hearing impairment in 2018 in two unrelated Dutch
    families. Every subsequent family in the literature is an independent LMX1A family. But
    no published report identifies an LMX1A variant in the Norwegian pedigree, so the
    equation of the locus with the gene rests on positional plausibility plus replication
    in other families rather than on solving the founding one.

    Two things follow. First, the phenotype MONDO attributes to DFNA7 is the Norwegian
    family's progressive high-tone loss, whereas the phenotype the LMX1A literature
    describes is progressive asymmetric loss across frequencies with vestibular
    involvement in about half of cases. Those are not obviously the same description, and
    if they are not the same disease the label is doing two jobs. Second, the interval is
    large and gene-dense, so an alternative gene in 1q21-q23 accounting for the Norwegian
    family is not excluded by anything published.

    This is recorded rather than resolved because it does not change how the entry is
    curated: everything in the pathograph below comes from molecularly confirmed LMX1A
    families. It changes what the entry's name should be taken to guarantee.
  evidence:
  - reference: PMID:8842739
    reference_title: "Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of recombinant individuals maps the deafness gene (DFNA7) to a 22 cM region between D1S104 and D1S466."
    explanation: >-
      The locus definition. A 22 cM interval is what the DFNA7 label originally denoted,
      and the founding paper stops at localisation.
  - reference: PMID:8842739
    reference_title: "Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The region contains several attractive candidate genes."
    explanation: >-
      The founding authors' own statement that the interval held multiple candidates, which
      is why positional plausibility alone does not settle the assignment.
  - reference: PMID:8842739
    reference_title: "Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The present report describes a large Norwegian family with autosomal dominant non-syndromic, progressive high tone hearing loss with linkage to 1q21-q23."
    explanation: >-
      Graded PARTIAL because it describes a phenotype that is not quite the one the LMX1A
      families show. High-tone loss is not the asymmetric, all-frequency picture reported
      for molecularly confirmed LMX1A carriers.
  - reference: PMID:29754270
    reference_title: "Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we identified heterozygous pathogenic missense variants of LMX1A in two families of Dutch origin with progressive nonsyndromic hearing impairment (HI), using whole exome sequencing."
    explanation: >-
      The gene assignment, made 22 years later in a different population, with no reference
      to the founding family.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Autosomal Dominant Nonsyndromic Hearing Loss 7 (DFNA7): Disease-Characteristics Report
Edison Scientific Literature 28 citations 2026-08-28T11:41:47.662726

Autosomal Dominant Nonsyndromic Hearing Loss 7 (DFNA7): Disease-Characteristics Report

Executive summary

Autosomal dominant nonsyndromic hearing loss 7 (DFNA7) is a rare Mendelian sensorineural hearing-loss disorder caused by heterozygous pathogenic variants in LMX1A, a LIM-homeodomain transcription-factor gene at 1q23.3. The best-supported phenotype is bilateral but frequently asymmetric sensorineural hearing loss (SNHL), with congenital through adult onset, usually a downsloping/high-frequency audiogram, variable mild-to-profound severity, and frequent progression. Vestibular dysfunction occurs in a subset and affected individuals otherwise lack a consistent syndromic phenotype. Human functional studies support haploinsufficiency, while mouse models establish LMX1A roles in cochlear and vestibular patterning, sensory-epithelium segregation, stria-vascularis differentiation, and generation of the endocochlear potential. No DFNA7-specific disease-modifying therapy or clinical trial was identified; present care consists of surveillance, hearing aids, cochlear implantation when indicated, vestibular management, communication support, and genetic counseling. (wesdorp2018heterozygousmissensevariants pages 8-9, wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10)

Domain Key findings Ontology suggestions Evidence strength/type
Identity / disease class Autosomal dominant nonsyndromic hearing loss 7 (DFNA7) is a Mendelian, nonsyndromic sensorineural hearing-loss entity associated with LMX1A; Open Targets lists MONDO:0011074 for this disease-target association. Evidence is from aggregated disease resources plus small family-based human studies, not EHR-derived population datasets. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, alde2023autosomaldominantnonsyndromic pages 3-4) MONDO:0011074; nonsyndromic hearing impairment concept Moderate; curated disease-resource + human genetic studies
Locus / gene Cytogenetic location reported as 1q23.3; gene LMX1A encodes a LIM-homeobox transcription factor important for inner-ear development and maintenance. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, alde2023autosomaldominantnonsyndromic pages 3-4, lee2020novelgenotype–phenotypecorrelation pages 1-2) Gene: LMX1A; UBERON: inner ear, cochlea, vestibular system Strong for gene-disease association; human + model evidence
Inheritance Predominantly autosomal dominant; several families show vertical transmission, and de novo heterozygous variants have also been reported. (wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10) HP: Autosomal dominant inheritance Strong; human pedigree/segregation evidence
Core phenotype Core presentation is sensorineural hearing loss (SNHL), usually bilateral but often asymmetric, commonly with downsloping/high-frequency configuration and variable severity from mild to profound. Suggested HPO terms: hearing impairment, sensorineural hearing impairment, asymmetric hearing impairment, progressive hearing impairment, high-frequency/sloping audiogram. (wesdorp2018heterozygousmissensevariants pages 8-9, jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4) HPO suggestions: sensorineural hearing impairment; progressive hearing impairment; asymmetric hearing impairment; high-frequency hearing impairment Strong; human clinical cohorts
Onset / temporal course Onset is highly variable: congenital/prelingual cases and postlingual cases are both reported; 2023 review summarizes onset from 1st–6th decade with progressive course. In the 2018 series, onset ranged from congenital to 35 years and was often in the 2nd–3rd decade. Disease is typically lifelong, not remitting. (alde2023autosomaldominantnonsyndromic pages 3-4, wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 8-9) HPO suggestions: congenital onset; childhood onset; adult onset; progressive course Strong; review + primary human data
Vestibular involvement Vestibular dysfunction is a recurrent but variable feature: the 2018 study states about half of affected individuals had vestibular dysfunction/symptoms; abnormalities included absent cVEMPs and caloric abnormalities, with symptoms appearing in adulthood and seeming progressive. In the 2022 cohort, one patient had hearing fluctuation with intermittent vertigo/headache suggestive of Menière-like episodes. (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6, jo2022geneticloadof pages 8-10) HPO suggestions: vestibular dysfunction, vertigo, abnormal caloric test, absent vestibular evoked myogenic potentials Moderate-strong; small human cohorts with formal vestibular testing
Key pathogenic variants Reported heterozygous disease-associated variants include c.290G>C (p.Cys97Ser), c.721G>C (p.Val241Leu), c.595A>G (p.Arg199Gly), c.622C>T (p.Arg208*), c.887dup (p.Gln297Thrfs*41), c.719A>G (p.Gln240Arg), c.721G>A (p.Val241Met), and c.331del (p.Gln111Argfs*7). Most are ultra-rare/absent in population databases in the cited cohorts. (wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10, wesdorp2018heterozygousmissensevariants pages 4-6) Variant classes: missense, nonsense, frameshift; germline heterozygous variants Strong for listed reported variants; human molecular studies
Mechanism / pathophysiology Human functional data support haploinsufficiency rather than dominant-negative effect for dominant LMX1A hearing loss. Reduced transcriptional activity correlates with more severe phenotype; p.Arg199Gly had near-abolished activity and severe congenital SNHL, whereas p.Cys97Ser/p.Val241Leu retained more activity and caused later progressive NSHL. Upstream/downstream developmental links from models include regulation involving Lmo4, Bmp6, Atoh1, Pax2, Wnt-related patterning, and strial differentiation markers. (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2, huang2018reciprocalnegativeregulation pages 1-2, iskusnykh2026anlmx1aballelic pages 1-2, renauld2025lmx1aisessential pages 1-2, nichols2008lmx1aisrequired pages 11-12) GO suggestions: DNA-binding transcription factor activity; inner ear development; sensory epithelium development; stria vascularis development Strong for transcriptional dysfunction/haploinsufficiency; human in vitro + mouse developmental models
Anatomy / tissues / cell types Primary anatomy: cochlea, organ of Corti, stria vascularis, Reissner’s membrane, endolymphatic duct/sac, vestibular organs, and spiral ganglion/cerebellar-brainstem auditory circuitry in models. Cell-type suggestions include hair cells, marginal cells, intermediate cells, spiral ganglion neurons, and non-sensory epithelial cells. Single-cell evidence identified an Lmx1a-positive type I spiral ganglion neuron population in mouse cochlea. (renauld2025lmx1aisessential pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12, grandi2020singlecellrnaanalysis pages 1-2) UBERON suggestions: cochlea, organ of Corti, stria vascularis, vestibular labyrinth; CL suggestions: hair cell, marginal cell, intermediate cell, spiral ganglion neuron; GO CC suggestions: nucleus Moderate-strong; mostly model-organism anatomy/cell evidence
Diagnostics Current diagnosis is based on audiologic phenotyping, serial follow-up for progression/asymmetry, vestibular testing when symptomatic, temporal-bone CT to exclude malformations/other causes, and molecular testing using hearing-loss gene panels or WES with segregation/ACMG interpretation; WGS is a reasonable escalation in unsolved hearing-loss cases generally, but no DFNA7-specific testing guideline was found. (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6, jo2022geneticloadof pages 8-10) HPO suggestions for workup: abnormal auditory brainstem response; abnormal vestibular testing Moderate; disease-specific cohort methods + general hearing-loss practice inference
Treatment / real-world care No DFNA7-specific drug or gene therapy was identified. Real-world management is supportive: hearing aids for milder/moderate disease and cochlear implantation (CI) for advanced loss. In the 2022 LMX1A series, one patient underwent unilateral CI with significant speech-perception improvement at 3 and 6 months post-op; the same paper notes favorable CI outcomes in LMX1A-related cases. (jo2022geneticloadof pages 8-10, jo2022geneticloadof pages 4-5) NCIT suggestions: hearing aid device; cochlear implantation; vestibular rehabilitation; genetic counseling Moderate; small human rehabilitation cohort
Epidemiology / population Disease-specific prevalence and incidence are not available. Evidence comes from very small reported series: 2018 described two Dutch families; 2022 identified nine patients from six LMX1A-associated families in two tertiary centers. No robust penetrance, sex ratio, founder mutation, carrier frequency, or geographic prevalence data were found. (wesdorp2018heterozygousmissensevariants pages 1-2, jo2022geneticloadof pages 8-10) Rare disease; familial autosomal dominant hearing loss Limited; case-series level
Environmental factors / modifiers No validated DFNA7-specific environmental risk or protective factors were identified. The 2018 study excluded obvious acquired causes of hearing loss in examined subjects, but formal gene-environment interactions remain unproven. General hearing-conservation advice is still clinically sensible but is not DFNA7-specific evidence. (wesdorp2018heterozygousmissensevariants pages 4-6, wesdorp2018heterozygousmissensevariants pages 8-9) HPO/Exposure suggestions not disease-specific Limited; absence-of-evidence statement
Model organisms Mouse Lmx1a null/dreher models show severe cochlear and vestibular malformations, loss/fusion of sensory epithelia, abnormal stria vascularis formation, absent endocochlear potential, and deafness; these models are mechanistically informative but more severe than human dominant DFNA7. Heterozygous mice may have normal hearing, highlighting translational limitations. (wesdorp2018heterozygousmissensevariants pages 8-9, renauld2025lmx1aisessential pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12) NCBI Taxon suggestion: Mus musculus; phenotype suggestions: deafness, vestibular dysfunction Strong for mechanism; indirect for exact human phenotype
Evidence gaps / curation cautions Gaps include: original historical linkage details not fully retrieved here; no disease-specific epidemiology; no validated penetrance estimates; no confirmed modifier genes, protective factors, omics biomarkers, or epigenetic signatures; no registered DFNA7-specific interventional trial identified; and several ontology IDs beyond MONDO/HPO high-level terms would require manual validation before KB ingestion. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, jo2022geneticloadof pages 8-10, qi2026genetherapyfor pages 4-6) Manual validation recommended for HPO/GO/CL/UBERON mappings Strong for identified gaps because evidence is sparse/no direct studies

Table: This table summarizes high-yield knowledge-base facts for autosomal dominant nonsyndromic hearing loss 7 associated with LMX1A, including phenotype, mechanism, diagnostics, treatment, and evidence gaps. It is designed as a compact curation aid grounded in the available cited human and model-organism evidence.

1. Disease information

Definition and identifiers

DFNA7 is an autosomal-dominant, predominantly nonsyndromic cochleovestibular disorder associated with monoallelic LMX1A variants. Open Targets records the association as MONDO:0011074, with LMX1A/ENSG00000162761 as its associated target. The cytogenetic locus is 1q23.3. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, alde2023autosomaldominantnonsyndromic pages 3-4)

Recommended identifiers and labels are:

  • Preferred name: autosomal dominant nonsyndromic hearing loss 7
  • Synonyms: DFNA7; deafness, autosomal dominant 7; LMX1A-related autosomal dominant nonsyndromic hearing loss; LMX1A-related dominant hearing impairment
  • MONDO: MONDO:0011074
  • Gene: LMX1A, LIM homeobox transcription factor 1 alpha; Ensembl ENSG00000162761
  • Gene OMIM: LMX1A, MIM 600298
  • Broad phenotype OMIM concept: hereditary nonsyndromic hearing impairment, MIM 500008, as used in the foundational study; a disease-specific OMIM number was not independently verified from the retrieved evidence.
  • ICD-10/ICD-11 and MeSH: no DFNA7-specific billing or subject-heading code was established. Use the applicable broader sensorineural/genetic hearing-loss code, recording MONDO and molecular diagnosis separately.

The evidence is mainly aggregated disease-resource information and family-level research cohorts, not individual longitudinal EHR data. Open Targets integrates five disease-target evidence records; the primary human literature comprises small pedigrees and tertiary-center series. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, jo2022geneticloadof pages 8-10)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The primary cause is a germline heterozygous pathogenic or likely pathogenic LMX1A variant. Familial vertical transmission and de novo variants are both documented. In 2018, whole-exome sequencing identified p.Val241Leu and p.Cys97Ser in two Dutch families; p.Val241Leu was de novo, while p.Cys97Ser segregated with dominant hearing loss. The latter was absent from gnomAD in that study. (PMID: 29754270; published May 12, 2018; DOI/URL: https://doi.org/10.1007/s00439-018-1880-5). (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6)

Risk factors

  • Genetic: carrying a pathogenic heterozygous LMX1A allele is the major risk factor. Family history is important but not required because de novo disease occurs.
  • Age: risk of clinically detectable impairment increases with age for later-onset progressive alleles, although severe congenital presentations also occur.
  • Sex: no reproducible sex effect is established.
  • Family history: an affected parent implies an approximately 50% transmission probability for each pregnancy, assuming a constitutional heterozygous variant.
  • Environmental/acquired factors: no DFNA7-specific toxin, infection, diet, smoking exposure, or occupational risk has been demonstrated.

The 2018 cohort specifically investigated acquired causes and found none sufficient to explain the familial SNHL. One patient also had fenestral otosclerosis, illustrating that genetic and acquired/concurrent disorders can coexist. (wesdorp2018heterozygousmissensevariants pages 4-6)

Protective factors and gene–environment interaction

No protective LMX1A variants, modifier alleles, diet, medication, or lifestyle intervention has been validated. The marked intrafamilial variability led investigators to propose environmental and/or genetic modifiers, including expression of the remaining wild-type LMX1A allele, but this remains a hypothesis rather than an established interaction. Avoidance of excessive noise and ototoxic exposure is prudent hearing conservation, but it has not been shown specifically to alter DFNA7 penetrance or progression. (wesdorp2018heterozygousmissensevariants pages 8-9)

3. Phenotypes

Core hearing phenotype

The principal manifestation is sensorineural hearing impairment, usually bilateral and often asymmetric. The overall audiogram is commonly downsloping, reflecting greater high-frequency impairment. Severity ranges from mild to profound and varies substantially within and between families. Suggested terms include HP:0000365—hearing impairment, HP:0000407—sensorineural hearing impairment, progressive hearing impairment, high-frequency hearing impairment, and asymmetric hearing impairment; exact subordinate HPO identifiers should be ontology-validated before ingestion. (wesdorp2018heterozygousmissensevariants pages 8-9, alde2023autosomaldominantnonsyndromic pages 3-4, wesdorp2018heterozygousmissensevariants pages 4-6)

A 2023 DFNA review summarized DFNA7 as congenital-to-adult onset across the first through sixth decades, with a sloping, progressive phenotype and possible vertigo. This is a synthesis rather than a disease-specific natural-history cohort (published June 2023; DOI: https://doi.org/10.3390/biomedicines11061616). (alde2023autosomaldominantnonsyndromic pages 3-4)

Quantitative clinical evidence

In the 2022 two-center series, nine patients from six LMX1A families were identified. Five of nine had an interaural difference greater than 15 dB; reported mean asymmetry was 35.75 dB, range 15–65 dB. Three of four patients with follow-up audiometry had progressive hearing loss. Individual asymmetries in the clinical table included 18, 36, 45, and 61 dB. (PMID: 36519758; published August 30, 2022; DOI: https://doi.org/10.3390/biomedicines10092125). (jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10)

The 2018 report found onset from congenital to 35 years, usually in the second or third decade, with mild-to-profound, generally downsloping and progressive impairment. Its abstract states: “Large variability was observed in the age of onset (a)symmetry, severity and progression rate of HI.” (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6, wesdorp2018heterozygousmissensevariants pages 8-9)

Vestibular and related manifestations

Approximately half of affected members in the 2018 study displayed vestibular dysfunction and symptoms. Absent cervical vestibular-evoked myogenic potentials up to 100 dBnHL implicated saccular dysfunction; caloric and rotary-chair abnormalities were also observed. Adult onset and greater abnormalities in older individuals suggested progression, although longitudinal vestibular data were unavailable. Suggested HPO concepts are vestibular dysfunction, vertigo, abnormal caloric response, and absent cVEMP. (wesdorp2018heterozygousmissensevariants pages 8-9, wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6)

One 2022 patient had fluctuating unilateral hearing, intermittent vertigo, and headache considered suggestive of coexisting Ménière disease. This should not be generalized as the canonical DFNA7 phenotype. (jo2022geneticloadof pages 8-10)

Syndromic exclusions and quality of life

Normal cognition and absence of consistent neurologic, skeletal, pigmentation, reproductive, or cutaneous abnormalities were reported in the Dutch families. The abstract explicitly states: “Although Lmx1a mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic features were present in the participating subjects of either family.” (wesdorp2018heterozygousmissensevariants pages 1-2)

Disease-specific EQ-5D, SF-36, PROMIS, employment, educational, or psychosocial statistics are unavailable. Expected morbidity arises from impaired speech perception, communication, localization—especially with asymmetry—and possibly balance; severity depends on onset, progression, rehabilitation, and access to communication accommodations.

4. Genetic and molecular information

Causal gene and protein

LMX1A encodes a nuclear LIM-homeodomain transcription factor. The protein contains two cysteine-rich LIM domains that mediate protein–protein interactions and a homeodomain responsible for sequence-specific DNA binding. (lee2020novelgenotype–phenotypecorrelation pages 1-2)

Reported dominant variants

Reported heterozygous DFNA7-associated variants include:

  • NM_177398.4:c.290G>C, p.(Cys97Ser): missense; second LIM domain; disrupts a zinc-binding residue; segregated in a Dutch family and was absent from gnomAD in the 2018 analysis.
  • c.721G>C, p.(Val241Leu): de novo missense; DNA-binding homeodomain.
  • c.595A>G, p.(Arg199Gly): de novo missense; homeodomain; classified likely pathogenic in the source study; severe congenital asymmetric SNHL.
  • c.622C>T, p.(Arg208Ter): nonsense.
  • c.887dup, p.(Gln297ThrfsTer41): frameshift.
  • c.719A>G, p.(Gln240Arg): missense.
  • c.721G>A, p.(Val241Met): missense.
  • c.331del, p.(Gln111ArgfsTer7): frameshift, reported as novel in 2022.

Most variants were absent from the population resources consulted by the reporting laboratories. Current ClinVar assertions, transcript normalization, genome build, read evidence, and gnomAD frequency should nevertheless be rechecked variant by variant before clinical reporting. All are germline; no somatic DFNA7 mechanism is known. (lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10, wesdorp2018heterozygousmissensevariants pages 4-6)

The p.Arg199Gly case was detected after abnormal newborn screening in a three-month-old boy. Reporter assays showed near-abolished transcriptional activity and no dominant-negative effect. The abstract states: “Further, our dominant LMX1A variant exerted pathogenic effects via haploinsufficiency rather than dominant-negative effect.” (PMID: 32840933; published September 2020; DOI: https://doi.org/10.1002/humu.24095). (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2)

Genotype–phenotype relationship

Residual transcriptional activity appears related to clinical severity: p.Arg199Gly produced the largest functional deficit and congenital severe-to-profound loss, whereas p.Cys97Ser and p.Val241Leu produced moderate reductions and later progressive disease. This relationship is biologically coherent but remains based on very few variants and should not be treated as a validated predictive model. (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2)

Modifiers, epigenetics, and structural variation

No validated modifier gene, methylation signature, histone alteration, or DFNA7-specific chromatin profile has been reported. A heterozygous 1q23.3–q24.1 deletion encompassing LMX1A in a separate patient supports dosage sensitivity, but large deletions may cause additional manifestations through neighboring genes. No recurrent DFNA7-specific translocation, inversion, aneuploidy, or copy-number syndrome is established. (wesdorp2018heterozygousmissensevariants pages 8-9)

5. Environmental and infectious information

DFNA7 is not caused by infection, radiation, pollution, diet, smoking, alcohol, or occupational exposure. No infectious trigger or zoonotic agent applies. Noise, ototoxic medication, aging, otitis, and other common causes may add independent hearing burden and should be assessed clinically, but their interaction with LMX1A has not been quantified. There are no DFNA7-specific CHEBI annotations beyond chemicals used in routine testing or treatment.

6. Mechanism and pathophysiology

Human causal chain

The best-supported chain is:

heterozygous LMX1A variant → impaired LIM-domain complex formation or homeodomain DNA binding → reduced transcriptional activity/haploinsufficiency → inadequate regulation or maintenance of cochleovestibular epithelial and neural programs → progressive dysfunction or loss of auditory/vestibular cells and ionic homeostasis → downsloping SNHL, asymmetry, and sometimes vestibular dysfunction. (wesdorp2018heterozygousmissensevariants pages 8-9, lee2020novelgenotype–phenotypecorrelation pages 1-2)

For later-onset alleles, one normal copy appears sufficient for gross embryonic development but insufficient for lifelong cochleovestibular maintenance. For severe alleles such as p.Arg199Gly, transcriptional function may fall below a developmental threshold, producing congenital disease. The 2018 authors summarized this uncertainty directly: “We propose that a single LMX1A wild-type copy is sufficient for normal development but insufficient for maintenance of cochleovestibular function.” (wesdorp2018heterozygousmissensevariants pages 1-2)

Developmental and cellular mechanisms from models

Mouse studies place Lmx1a upstream of sensory versus nonsensory epithelial segregation and vestibular/cochlear morphogenesis. Reciprocal negative regulation between Lmx1a and Lmo4 patterns sensory cristae, semicircular canals, utricle, endolymphatic duct, and basal cochlear hair cells. Other implicated networks include Wnt/Otx patterning, Delta–Notch-related sensory segregation, and regulation of Pax2, Fgf8, Sox2, Atoh1, Prox1, Hmx2/3, and Bmp6-dependent progenitors. These are model-derived pathways, not all proven direct targets in human DFNA7. (huang2018reciprocalnegativeregulation pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12)

Recent mechanistic work showed that Lmx1a-null mice fail to differentiate a normal stria vascularis: marginal-cell proteins BSND and KCNQ1 and intermediate-cell marker CD44 are lost, pendrin/SLC26A4 expression expands abnormally, intermediate cells disappear, and the normal approximately 80–100 mV endocochlear potential is absent. This provides a plausible downstream ionic-homeostasis mechanism, but the study was published in 2025 and used recessive-null mice rather than human heterozygous DFNA7 tissue (DOI: https://doi.org/10.3389/fcell.2025.1537505). (renauld2025lmx1aisessential pages 1-2)

Suggested GO concepts include DNA-binding transcription-factor activity, transcriptional regulation, inner-ear development, sensory-organ morphogenesis, auditory-receptor-cell development, sensory-epithelium development, cell-fate specification, ion homeostasis, stria-vascularis development, and maintenance of sensory cells. The principal subcellular compartment is the nucleus.

Molecular profiling and advanced technologies

Single-cell qPCR in mouse cochlea identified an Lmx1a-positive type-I spiral ganglion neuron population at postnatal days P3, P8, and P12, distinct from Slc4a4- and Mfap4/Fzd2-marked populations. This suggests early molecular specification of auditory-afferent subtypes, but it does not establish that these neurons are the primary lesion in human DFNA7 (DOI: https://doi.org/10.3389/fnmol.2020.00083). (grandi2020singlecellrnaanalysis pages 1-2)

No DFNA7 patient-tissue transcriptome, proteome, metabolome, lipidome, spatial-transcriptomic atlas, CRISPR screen, or integrated patient multi-omics signature was found. There is no established immune, inflammatory, fibrotic, ischemic, or metabolic component.

7. Anatomical structures affected

The principal organ is the inner ear. Relevant sites are the cochlea and organ of Corti, cochlear sensory and nonsensory epithelia, stria vascularis, Reissner membrane, endolymphatic duct and sac, semicircular canals, utricle, saccule, and spiral ganglion. Human CT generally showed no major cochleovestibular malformation in later-onset heterozygous disease. (wesdorp2018heterozygousmissensevariants pages 1-2, renauld2025lmx1aisessential pages 1-2, nichols2008lmx1aisrequired pages 11-12)

Suggested mappings are:

  • UBERON: inner ear, cochlea, organ of Corti, stria vascularis, vestibular labyrinth, saccule, utricle, semicircular canal, spiral ganglion.
  • CL: inner/outer hair cell, sensory epithelial cell, nonsensory epithelial cell, strial marginal cell, strial intermediate cell/melanocyte-lineage cell, spiral ganglion neuron.
  • GO cellular component: nucleus and transcription-factor complex.

Hearing loss is usually bilateral but can be markedly asymmetric. Major secondary-organ involvement is not expected in human DFNA7.

8. Temporal development

Onset ranges from congenital/prelingual disease to childhood, adolescence, or adulthood. The 2023 review gives a first-to-sixth-decade range. Course is chronic and commonly progressive rather than episodic or remitting, although fluctuation was reported in one patient with possible coexisting Ménière disease. (jo2022geneticloadof pages 4-5, jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4)

Practical stages are not formally standardized but can be represented as: early high-frequency or asymmetric loss; broader-frequency moderate/severe loss with reduced speech perception; and advanced severe-to-profound loss potentially requiring cochlear implantation. Critical intervention windows include early childhood for congenital disease and any period when serial audiometry documents declining aided speech access. No spontaneous remission has been demonstrated.

9. Inheritance and population

Inheritance is autosomal dominant, with de novo disease recognized. Penetrance is likely age- and allele-dependent but has not been measured robustly. Expressivity is clearly variable in onset, symmetry, progression, vestibular involvement, and severity. Anticipation, germline mosaicism, founder effects, consanguinity effects, and carrier frequency have not been established. Consanguinity is not expected to be a major factor in dominant DFNA7, although biallelic LMX1A disease is a separate severe recessive phenotype. (wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4)

No population prevalence, incidence, sex ratio, or reliable ethnic/geographic enrichment is available. Published cases include Dutch and Korean clinical cohorts, but these ascertainment locations do not prove population enrichment. The two-center 2022 study found nine LMX1A patients from six families among a broader molecularly tested referral cohort; this is not a population-prevalence estimate. (jo2022geneticloadof pages 8-10)

10. Diagnostics

Clinical evaluation

Recommended assessment comprises history of onset and progression; three-generation pedigree; otoscopy; pure-tone air/bone audiometry; speech audiometry; tympanometry; otoacoustic emissions and auditory brainstem response when age or reliability warrants; and serial testing of each ear because asymmetry and progression are common. Vestibular history and examination should be followed by vHIT, caloric/rotary-chair testing, and cVEMP when imbalance or vertigo is present. Temporal-bone CT or MRI is used selectively to evaluate marked asymmetry, cochlear-implant anatomy, or alternative pathology, not as a molecular diagnostic test. (wesdorp2018heterozygousmissensevariants pages 1-2, wesdorp2018heterozygousmissensevariants pages 4-6)

There is no blood chemistry, metabolite, circulating protein, biopsy, or histopathologic biomarker for DFNA7.

Genetic testing strategy

  1. Use a comprehensive hereditary-hearing-loss panel that includes LMX1A, with copy-number analysis and adequate coverage of relevant exons/splice regions.
  2. If negative or the presentation is atypical, use trio/family WES and segregation analysis; WES identified the founding dominant variants.
  3. Escalate unresolved cases to WGS to detect cryptic splice, regulatory, mitochondrial, and structural variants, although this is general hearing-loss practice rather than DFNA7-specific evidence.
  4. Confirm reportable variants by an orthogonal method when appropriate, review ClinVar/gnomAD, and apply current ACMG/AMP criteria with phenotype and segregation evidence.

Single-gene LMX1A sequencing is reasonable when the phenotype and family variant are known. CMA may detect a deletion encompassing LMX1A but is lower yield for sequence variants. Routine karyotype, FISH, mitochondrial testing, and repeat-expansion testing are not indicated unless another diagnosis is suspected. RNA studies can clarify suspected splice variants but are not routine DFNA7 diagnostics.

Differential diagnosis and screening

Differentials include other dominant nonsyndromic hearing-loss genes—especially KCNQ4, TECTA, WFS1, POU4F3, EYA4, ACTG1, MYO6, COCH, and MYO7A—as well as age/noise-related loss, congenital CMV, ototoxicity, Ménière disease, otosclerosis, and syndromic conditions initially presenting with isolated hearing loss. The combination of frequent asymmetry, progression, occasional vestibular dysfunction, and LMX1A variant is suggestive but not diagnostic by phenotype alone.

Universal newborn hearing screening can detect congenital severe alleles but will miss later-onset DFNA7. Once a familial pathogenic variant is established, offer cascade testing and baseline/serial audiometry to at-risk relatives, including those currently asymptomatic.

11. Outcome and prognosis

DFNA7 is not known to reduce survival or life expectancy, and disease-specific mortality is not reported. Morbidity is auditory and sometimes vestibular. Hearing may progress to severe or profound levels, but rate and final severity are allele- and person-dependent. Major prognostic features are age at onset, baseline thresholds, progression, asymmetry, speech discrimination, vestibular involvement, and access to timely amplification or implantation. No validated molecular prognostic biomarker exists beyond preliminary variant-function correlations. (lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10)

Spontaneous recovery is not expected. Functional outcomes can improve substantially with rehabilitation. In the 2022 series, one patient whose left ear progressed to profound loss underwent unilateral cochlear implantation and had significant speech-perception improvement at three and six months. (jo2022geneticloadof pages 8-10)

12. Treatment and applications

Current standard care

  • Hearing aids: first-line for aidable mild-to-severe loss; fit each ear according to thresholds and speech needs.
  • Cochlear implantation: consider for severe-to-profound loss with inadequate aided speech recognition. The available LMX1A evidence is favorable but limited to very small numbers.
  • Vestibular care: vestibular rehabilitation and disorder-specific management when objective dysfunction or imbalance is present.
  • Communication/rehabilitation: speech-language therapy where needed, assistive listening devices, classroom/workplace accommodations, captioning, and sign-language access according to patient preference.
  • Surveillance: long-term audiometry is important because progression and interaural divergence may alter device candidacy.

Suggested NCIT concepts are Hearing Aid, Cochlear Implantation, Audiologic Rehabilitation, Vestibular Rehabilitation, Speech Therapy, and Genetic Counseling; exact NCIT identifiers should be validated before database loading. (jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4)

Pharmacologic and advanced therapies

No drug, pharmacogenomic algorithm, surgery that corrects LMX1A dysfunction, cell therapy, ASO, siRNA, CRISPR treatment, or LMX1A gene therapy is approved or clinically validated. A search specifically for DFNA7/LMX1A trials found no relevant registered interventional study. The widely publicized 2024 hereditary-deafness gene-therapy advances concern biallelic OTOF/DFNB9, including seven reported trials, not dominant LMX1A disease; these results should not be extrapolated to DFNA7. (qi2026genetherapyfor pages 4-6)

For dominant haploinsufficiency, future strategies might include allele-agnostic augmentation or enhancement of residual LMX1A function, but developmental expression, nuclear transcriptional targeting, dosage control, delivery to multiple cochleovestibular cell types, and an uncertain treatment window remain substantial barriers.

13. Prevention

Primary prevention of a de novo or inherited pathogenic allele is not possible through lifestyle or vaccination. Reproductive options after identifying the family variant include genetic counseling, prenatal diagnosis, and preimplantation genetic testing, governed by patient values and local regulation. Predictive testing of minors can be clinically actionable because surveillance and hearing intervention are beneficial.

Secondary prevention consists of cascade testing, baseline audiology, serial monitoring, and prompt amplification or implantation. Tertiary prevention includes hearing conservation, avoidance of unnecessary ototoxic exposure, management of vestibular fall risk, and communication rehabilitation. These measures prevent additional disability rather than the underlying genotype. No vaccine or chemoprophylaxis applies.

14. Other species and natural disease

The principal comparative species is Mus musculus (NCBI Taxonomy 10090), with ortholog Lmx1a. Naturally occurring and induced mouse alleles include dreher, mutanlallemand, and belly-spot-and-deafness. Homozygous animals are deaf and display vestibular behaviors such as circling and head tossing, with absent endolymphatic ducts/semicircular canals, shortened cochlear ducts, sensory-patch abnormalities, and truncated Lmx1a protein. (DOI: https://doi.org/10.1371/journal.pone.0051065). (huang2018reciprocalnegativeregulation pages 1-2, nichols2008lmx1aisrequired pages 11-12)

These are hereditary laboratory-animal phenotypes, not a recognized contagious veterinary disease; breed-specific natural disease, VBO terms, zoonotic transmission, and cross-species infection are not applicable. Conservation of Lmx1-family auditory-development functions supports comparative utility, but species differ in dosage sensitivity.

15. Model organisms

Mouse genetic models

Recessive-null/dreher, spontaneous splice/deletion alleles, and conditional knockouts model Lmx1a loss. They reproduce deafness and vestibular dysfunction and reveal developmental abnormalities in the cochlea, vestibular labyrinth, stria vascularis, and central auditory structures. Relevant applications include studying sensory-epithelial segregation, ion homeostasis, hair-cell maintenance, vestibular morphogenesis, and interactions with Lmx1b/Lmo4/Wnt/BMP programs. (huang2018reciprocalnegativeregulation pages 1-2, renauld2025lmx1aisessential pages 1-2, chizhikov2021lmx1aandlmx1b pages 1-2, nichols2008lmx1aisrequired pages 11-12)

The major limitation is severity and inheritance mismatch: homozygous mouse nulls have profound multisystem developmental abnormalities, whereas human DFNA7 is heterozygous and usually nonsyndromic. Heterozygous mice had normal hearing through approximately three to four months in cited observations. Therefore, null-mouse anatomy supports biological plausibility but does not fully model human penetrance, progression, or asymmetry. (wesdorp2018heterozygousmissensevariants pages 8-9)

Cellular and in-vitro models

HEK293T luciferase assays quantify variant-specific LMX1A transcriptional activity and support haploinsufficiency and preliminary genotype–phenotype correlation. They cannot reproduce cochlear architecture, mechanical transduction, or long-term sensory-cell maintenance. Patient-derived iPSC inner-ear organoids, precise heterozygous knock-in animals, and longitudinal single-cell/spatial profiling would be higher-fidelity future models. (lee2020novelgenotype–phenotypecorrelation pages 2-4, lee2020novelgenotype–phenotypecorrelation pages 1-2)

Recent research and expert interpretation

The most important recent synthesis is the 2023 DFNA review, which places DFNA7 among more than 80 dominant hearing-loss loci and emphasizes long-term audiological follow-up to detect deterioration and trigger hearing-aid or cochlear-implant intervention. For DFNA7 specifically, however, the decisive human evidence remains the 2018 gene-discovery cohort, 2020 functional genotype–phenotype study, and 2022 tertiary-center series. (jo2022geneticloadof pages 8-10, alde2023autosomaldominantnonsyndromic pages 3-4)

A 2024 structural study of LMX1A homeodomain recognition of A/T-rich promoter motifs advances basic understanding of DNA binding but does not yet alter diagnosis or treatment (DOI: https://doi.org/10.1111/febs.17118). The latest mechanistic extension, published in 2025, identifies Lmx1a as essential for strial marginal-cell differentiation and endocochlear-potential generation in mice. Together these results strengthen a dual developmental-and-maintenance model but do not yet provide a therapeutic target validated in human DFNA7 tissue. (renauld2025lmx1aisessential pages 1-2)

Evidence limitations and curation cautions

DFNA7 evidence remains case-series level: no registry-scale natural-history study, prevalence estimate, prospective penetrance study, randomized treatment trial, patient-derived omics dataset, or validated environmental modifier exists. Several variants reported in research cohorts require current ClinVar and ACMG reassessment before clinical use. Mouse recessive-null findings must be labeled as model-organism evidence, and general hearing-loss recommendations must not be represented as DFNA7-specific efficacy data. The strongest directly supported knowledge-base assertions are the LMX1A association, autosomal-dominant/de novo inheritance, variable progressive SNHL with frequent asymmetry, occasional vestibular dysfunction, and haploinsufficiency mechanism. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A, wesdorp2018heterozygousmissensevariants pages 1-2, lee2020novelgenotype–phenotypecorrelation pages 2-4, jo2022geneticloadof pages 8-10)

References

  1. (wesdorp2018heterozygousmissensevariants pages 8-9): Mieke Wesdorp, P. A. M. de Koning Gans, M. Schraders, J. Oostrik, M. Huynen, H. Venselaar, A. Beynon, J. van Gaalen, Vitória Piai, N. Voermans, M. V. van Rossum, B. Hartel, Stefan H. Lelieveld, L. Wiel, B. Verbist, L. Rotteveel, M. V. van Dooren, P. Lichtner, H. Kunst, I. Feenstra, R. Admiraal, M. F. H. H. W. E. H. M. P. S. G. L. J. C. S. G. M. J. van Dooren de Gier Hoefsloot van der Schroeff Kant, M. V. van Dooren, H. D. de Gier, E. H. Hoefsloot, M. P. van der Schroeff, S. Kant, L. Rotteveel, S. Frints, J. Hof, R. Stokroos, E. Vanhoutte, R. Admiraal, I. Feenstra, H. Kremer, H. Kunst, R. Pennings, H. Yntema, A. V. van Essen, R. Free, J. S. Klein-Wassink, H. Yntema, L. Hoefsloot, R. Pennings, and H. Kremer. Heterozygous missense variants of lmx1a lead to nonsyndromic hearing impairment and vestibular dysfunction. Human Genetics, 137:389-400, May 2018. URL: https://doi.org/10.1007/s00439-018-1880-5, doi:10.1007/s00439-018-1880-5. This article has 43 citations and is from a peer-reviewed journal.

  2. (wesdorp2018heterozygousmissensevariants pages 1-2): Mieke Wesdorp, P. A. M. de Koning Gans, M. Schraders, J. Oostrik, M. Huynen, H. Venselaar, A. Beynon, J. van Gaalen, Vitória Piai, N. Voermans, M. V. van Rossum, B. Hartel, Stefan H. Lelieveld, L. Wiel, B. Verbist, L. Rotteveel, M. V. van Dooren, P. Lichtner, H. Kunst, I. Feenstra, R. Admiraal, M. F. H. H. W. E. H. M. P. S. G. L. J. C. S. G. M. J. van Dooren de Gier Hoefsloot van der Schroeff Kant, M. V. van Dooren, H. D. de Gier, E. H. Hoefsloot, M. P. van der Schroeff, S. Kant, L. Rotteveel, S. Frints, J. Hof, R. Stokroos, E. Vanhoutte, R. Admiraal, I. Feenstra, H. Kremer, H. Kunst, R. Pennings, H. Yntema, A. V. van Essen, R. Free, J. S. Klein-Wassink, H. Yntema, L. Hoefsloot, R. Pennings, and H. Kremer. Heterozygous missense variants of lmx1a lead to nonsyndromic hearing impairment and vestibular dysfunction. Human Genetics, 137:389-400, May 2018. URL: https://doi.org/10.1007/s00439-018-1880-5, doi:10.1007/s00439-018-1880-5. This article has 43 citations and is from a peer-reviewed journal.

  3. (lee2020novelgenotype–phenotypecorrelation pages 2-4): Sang‐Yeon Lee, Jin Hee Han, Marge Carandang, Min Young Kim, Bonggi Kim, Nayoung Yi, Jinho Kim, Bong Jik Kim, Doo‐Yi Oh, Ja‐Won Koo, Jun Ho Lee, Seung‐Ha Oh, and Byung Yoon Choi. Novel genotype–phenotype correlation of functionally characterized lmx1a variants linked to sensorineural hearing loss. Sep 2020. URL: https://doi.org/10.1002/humu.24095, doi:10.1002/humu.24095. This article has 23 citations and is from a domain leading peer-reviewed journal.

  4. (jo2022geneticloadof pages 8-10): Hyung Dong Jo, Jin Hee Han, So Min Lee, Dong Hwa Choi, Sang-Yeon Lee, and Byung Yoon Choi. Genetic load of alternations of transcription factor genes in non-syndromic deafness and the associated clinical phenotypes: experience from two tertiary referral centers. Biomedicines, 10(9):2125, Aug 2022. URL: https://doi.org/10.3390/biomedicines10092125, doi:10.3390/biomedicines10092125. This article has 11 citations.

  5. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 7-LMX1A): Open Targets Query (autosomal dominant nonsyndromic hearing loss 7-LMX1A, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (alde2023autosomaldominantnonsyndromic pages 3-4): Mirko Aldè, Giovanna Cantarella, Diego Zanetti, Lorenzo Pignataro, Ignazio La Mantia, Luigi Maiolino, Salvatore Ferlito, Paola Di Mauro, Salvatore Cocuzza, Jérôme René Lechien, Giannicola Iannella, Francois Simon, and Antonino Maniaci. Autosomal dominant non-syndromic hearing loss (dfna): a comprehensive narrative review. Biomedicines, 11:1616, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061616, doi:10.3390/biomedicines11061616. This article has 65 citations.

  7. (lee2020novelgenotype–phenotypecorrelation pages 1-2): Sang‐Yeon Lee, Jin Hee Han, Marge Carandang, Min Young Kim, Bonggi Kim, Nayoung Yi, Jinho Kim, Bong Jik Kim, Doo‐Yi Oh, Ja‐Won Koo, Jun Ho Lee, Seung‐Ha Oh, and Byung Yoon Choi. Novel genotype–phenotype correlation of functionally characterized lmx1a variants linked to sensorineural hearing loss. Sep 2020. URL: https://doi.org/10.1002/humu.24095, doi:10.1002/humu.24095. This article has 23 citations and is from a domain leading peer-reviewed journal.

  8. (wesdorp2018heterozygousmissensevariants pages 4-6): Mieke Wesdorp, P. A. M. de Koning Gans, M. Schraders, J. Oostrik, M. Huynen, H. Venselaar, A. Beynon, J. van Gaalen, Vitória Piai, N. Voermans, M. V. van Rossum, B. Hartel, Stefan H. Lelieveld, L. Wiel, B. Verbist, L. Rotteveel, M. V. van Dooren, P. Lichtner, H. Kunst, I. Feenstra, R. Admiraal, M. F. H. H. W. E. H. M. P. S. G. L. J. C. S. G. M. J. van Dooren de Gier Hoefsloot van der Schroeff Kant, M. V. van Dooren, H. D. de Gier, E. H. Hoefsloot, M. P. van der Schroeff, S. Kant, L. Rotteveel, S. Frints, J. Hof, R. Stokroos, E. Vanhoutte, R. Admiraal, I. Feenstra, H. Kremer, H. Kunst, R. Pennings, H. Yntema, A. V. van Essen, R. Free, J. S. Klein-Wassink, H. Yntema, L. Hoefsloot, R. Pennings, and H. Kremer. Heterozygous missense variants of lmx1a lead to nonsyndromic hearing impairment and vestibular dysfunction. Human Genetics, 137:389-400, May 2018. URL: https://doi.org/10.1007/s00439-018-1880-5, doi:10.1007/s00439-018-1880-5. This article has 43 citations and is from a peer-reviewed journal.

  9. (jo2022geneticloadof pages 4-5): Hyung Dong Jo, Jin Hee Han, So Min Lee, Dong Hwa Choi, Sang-Yeon Lee, and Byung Yoon Choi. Genetic load of alternations of transcription factor genes in non-syndromic deafness and the associated clinical phenotypes: experience from two tertiary referral centers. Biomedicines, 10(9):2125, Aug 2022. URL: https://doi.org/10.3390/biomedicines10092125, doi:10.3390/biomedicines10092125. This article has 11 citations.

  10. (huang2018reciprocalnegativeregulation pages 1-2): Yanhan Huang, Jennifer Hill, Andrew Yatteau, Loksum Wong, Tao Jiang, Jelena Petrovic, Lin Gan, Lijin Dong, and Doris K. Wu. Reciprocal negative regulation between lmx1a and lmo4 is required for inner ear formation. The Journal of Neuroscience, 38:5429-5440, Jun 2018. URL: https://doi.org/10.1523/jneurosci.2484-17.2018, doi:10.1523/jneurosci.2484-17.2018. This article has 23 citations.

  11. (iskusnykh2026anlmx1aballelic pages 1-2): Igor Y. Iskusnykh, Bernd Fritzsch, Ebenezer N. Yamoah, Ekaterina Y. Steshina, and Victor V. Chizhikov. An lmx1a/b allelic series reveals the role of lmx1 genes in cochlear nuclei development. Cell and Tissue Research, Apr 2026. URL: https://doi.org/10.1007/s00441-026-04064-7, doi:10.1007/s00441-026-04064-7. This article has 1 citations and is from a peer-reviewed journal.

  12. (renauld2025lmx1aisessential pages 1-2): Justine M. Renauld, Igor Y. Iskusnykh, Ebenezer N. Yamoah, Richard J. H. Smith, Corentin Affortit, David Z. He, Huizhan Liu, David Nichols, Judith Bouma, Mahesh K. Nayak, Xin Weng, Tianli Qin, Mai Har Sham, Victor V. Chizhikov, and Bernd Fritzsch. Lmx1a is essential for marginal cell differentiation and stria vascularis formation. Frontiers in Cell and Developmental Biology, Mar 2025. URL: https://doi.org/10.3389/fcell.2025.1537505, doi:10.3389/fcell.2025.1537505. This article has 9 citations.

  13. (nichols2008lmx1aisrequired pages 11-12): David H. Nichols, Sarah Pauley, Israt Jahan, Kirk W. Beisel, Kathleen J. Millen, and Bernd Fritzsch. Lmx1a is required for segregation of sensory epithelia and normal ear histogenesis and morphogenesis. Cell and Tissue Research, 334:339-358, Nov 2008. URL: https://doi.org/10.1007/s00441-008-0709-2, doi:10.1007/s00441-008-0709-2. This article has 155 citations and is from a peer-reviewed journal.

  14. (chizhikov2021lmx1aandlmx1b pages 1-2): Victor V. Chizhikov, Igor Y. Iskusnykh, Nikolai Fattakhov, and Bernd Fritzsch. Lmx1a and lmx1b are redundantly required for the development of multiple components of the mammalian auditory system. Jan 2021. URL: https://doi.org/10.1016/j.neuroscience.2020.11.013, doi:10.1016/j.neuroscience.2020.11.013. This article has 57 citations and is from a domain leading peer-reviewed journal.

  15. (grandi2020singlecellrnaanalysis pages 1-2): Fiorella Carla Grandi, Lara De Tomasi, and Mirna Mustapha. Single-cell rna analysis of type i spiral ganglion neurons reveals a lmx1a population in the cochlea. Frontiers in Molecular Neuroscience, May 2020. URL: https://doi.org/10.3389/fnmol.2020.00083, doi:10.3389/fnmol.2020.00083. This article has 32 citations.

  16. (qi2026genetherapyfor pages 4-6): Yu Qi, Fangzhi Tan, Maoli Duan, and Ling Lu. Gene therapy for non-syndromic hearing loss. Head and Neck Diseases Conflux, 2(1):e345, Mar 2026. URL: https://doi.org/10.71321/703b4949, doi:10.71321/703b4949. This article has 0 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 13
On topic 3
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 3
Resolved 3
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0

Every term resolved, and every label the report gave matched.